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PART I: STRUCTURAL INSIGHTS INTO THE BILOBAL REGULATION OF SMYD
PROTEINS
GENERAL INTRODUCTION
Post-Translational Modifications
Post-translational modifications (PTM) are covalent modifications made to a protein after
its translation by the ribosome. PTMs serve as central components in cell signaling, epigenetic
regulation, proteasomal degradation, and protein structure. These small modifications may seem
minor in comparison to a full size protein, but PTMs operate as vital mechanisms for organisms to
expand and dynamically control a protein’s function. Indeed, impaired post-translational
machinery are linked to several human diseases. Understanding how PTMs are directed in human
health are of strong interest among the research community.
PTMs can be divided into two categories: reversible and irreversible. Reversible
modifications are usually small functional groups, such as phosphate, methyl and acetyl groups,
attached to specific amino acid residues of a given protein, and these small chemical attachments
can influence the protein’s fold and function. Irreversible post-translational modifications include
peptide bond cleavage and cofactor attachments. These type of modifications are also necessary
for the protein maturation and function. While nature has many types of PTMs, my doctoral studies
focus on the structure and function lysine methyltransferases, ubiquitin-specific proteases and
disulfide-linked PDZ-domains.
SMYD proteins
SMYD (SET and MYND domain-containing proteins) proteins are histone and non-histone
lysine methyltransferases which contribute various cellular roles including cell cycle control,
chromatin remodeling, signal transduction and transcription [1-5]. Early reports demonstrated high
SMYD expression in cardiac and skeletal muscles and suggested SMYD functioned in myogenesis
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and cardiomyocyte differentiation [1, 6-12]; however, later reports found SMYD proteins to also
be involved in immunity and inflammation [13-15]. SMYD proteins are of therapeutic interest due
to a growing list of cancers associated with their overexpression and methylation activity,
particularly SMYD2 and SMYD3 [4, 5, 16-22]. The lysine methyltransferase of interest for my
project is SMYD2.
SMYD2 is overexpressed in many different cancers including but not limited to
esophageal, gastric, breast, leukemia and pancreatic cancers [16-19, 23]. The growing number of
reported cancers associated with SMYD2 expression and function highlight the importance of
studying the molecular mechanism of SMYD2. Crystal structures of SMYD2 have shed some light
into the mechanism of substrate and cofactor binding [24]; however, the mechanism at which
substrates are channeled through the substrate channel remains unclear. Chapters 1, 2, 3 and 4 will
explore the structure and function of SMYD proteins and examine how the TPR-like domain
influences the accessibility of the substrate channel in SMYD proteins.
Ubiquitin-specific proteases
Ubiquitin-specific proteases (USPs) are a large family of deubiquitinases consisting of 56
different members in humans. Each USP is responsible for recognizing a specific protein substrate
and ubiquitin branch type [25]. After deubiquitination, the protein of interest is recycled and
protected against proteasomal degradation. Since proteasomal inhibitors were approved by the
FDA for treating hematological malignancies, interest surrounding USPs as viable targets for
treating cancers, autoimmune and neurodegenerative diseases is growing [26]. Since USPs are
diverse class of enzymes upstream in the ubiquitin proteasome pathway, USPs serve as more
selective targets potentially offering fewer side effects [27].
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USP10 is one member of the USP family found to maintain p53 homeostasis, DNA repair
and androgen receptor-dependent transcription. While USP10 appears to function multiple
pathways, USP10’s role in cancer is well established. In mutant p53 renal cancers, USP10
stabilizes oncogenic p53 promoting cellular growth [28]. Another study found USP10 creates a
positive feedback loop in promoting androgen receptor transcription and G3BP2 expression
resulting in repressed p53 function in prostate cancers [29]. More recently, USP10 was found to
specifically deubiquitinate oncogenic FLT3-ITD, an oncogene commonly found in acute myeloid
leukemias [30]. Altogether, USP10 appears to be an attractive therapeutic target for specific cancer
treatments. Unfortunately, biochemical and structural studies of USP10 are currently lacking. In
Chapter 5, I designed a soluble protein construct that incorporates the catalytic domain of USP10
(USP10-CA). This protein construct was used to study the binding and biochemistry of USP10CA on reported inhibitors. Ultimately, our goal was to study the structure and function of USP10CA in order to profile the mechanism of deubiquitination and inhibition.
PDZ-domains
PDZ domains are small, protein-protein interacting modules that anchor protein complex
assembly. Humans possess roughly 260 proteins which possess either one or more PDZ domains
into the open reading frame [31]. Each PDZ domain is capable of recognizing four amino acid
motif, found at the carboxyl-end of target proteins. Disruption of PDZ-ligand interactions have
been well-documented in impair cellular signaling [32]. For example, C-X-C chemokine receptor
type 2 (CXCR2) is a membrane receptor capable of driving chemotaxis in neutrophils. Deleting
the PDZ-binding motif in CXCR2 disrupted the PDZ-mediated complex with Na+/H+ exchanger
regulatory factor-1 (NHERF1). Obstructing this complex attenuated CXCR2-dependent calcium
mobilization and chemotaxis migration in murine neutrophils [33].
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PDZ-domains are not necessarily noted for post-translational modifications; however, in
chapter 6, our study was initially aimed to understand the binding promiscuity of the CXCR2 PDZinteracting motif and PDZ-RhoGEF, but we identified a new disulfide bond link that appears to
covalently scaffold two PDZ-RhoGEF molecules. Disulfide bonds are commonly used in nature
to stabilize native and protein complex structures. In the case for PDZ-RhoGEF, disulfide bond
formation creates an anti-parallel structure capable of recognizing two CXCR2 peptides.
Interestingly, a separate study found disulfide bond formation of PDZ-RhoGEF and LARG, a
conserved relative of PDZ-RhoGEF, were important for promoting ligand binding [34]. Here, we
describe the structure and potential functional outcomes for this newly appreciated disulfide bond.
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CHAPTER 1 STRUCTURE AND FUNCTION OF SET AND MYND DOMAINCONTAINING PROTEINS
*Published in Int J Mol Sci. 2015 Jan 8;16(1):1406-28. doi: 10.3390/ijms16011406. All authors
agreed with including their work in this dissertation.
Introduction
SET and MYND domain-containing proteins (SMYD) are a special class of protein lysine
methyltransferases involved in methylation of histones and non-histone targets [1-5]. To date,
there are five members from the SMYD family, SMYD1–5 (Figure 1A) [6]. Each member contains
a conserved SET (Suppressor of variegation, Enhancer of Zeste, Trithorax) domain that is “split”
by a Myeloid-Nervy-DEAF1 (MYND) domain [35]. The SET domain is a conserved catalytic unit
for lysine methylation found in nearly all histone methyltransferases (HMT) [36]. The MYND
domain is a zinc finger motif that primarily functions as a protein–protein interaction module [37,
38]. Another feature is the C-terminal domain (CTD) found in SMYD1–4 but absent in SMYD5.
Despite the lack of sequence similarity, this domain is structurally similar to tetratricopeptide
repeats (TPR), which is a motif important for the binding of cochaperones with heat shock protein90 (Hsp90) [24, 35, 39, 40].
SMYD proteins may regulate chromatin remodeling and gene accessibility by methylating
histone targets and interacting with transcription mediators. SMYD1–3 methylate H3K4, which is
a methylation site promoting active transcription [1, 4, 35, 41, 42]. However, SMYD does not have
an effect on global H3K4 methylation but appears to impact selective promoter regions [43, 44].
SMYD1 binds directly to class I and class II histone deacetylases (HDAC) and represses
transcription from an SV40-luciferase reporter [1]. SMYD2 was also found to dimethylate H3K36
in vitro and repress transcription through interaction with the Sin3A histone deacetylase complex
[2]. However, it remains to be determined whether in vivo recruitment of Sin3A requires both
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H3K36 methylation and the presence of SMYD2. SMYD3 plays an important role in
transcriptional regulation as a member of an RNA polymerase complex [4]. SMYD3 interacts with
RNA polymerase II and RNA helicase HELZ suggesting that it might regulate target gene
expression by facilitating transcriptional elongation. In HEK293 cells, overexpression of SMYD3
was found to up-regulate a number of genes corresponding to oncogenes, homeobox genes, and
genes of the cell cycle [4]. These genes are highly expressed in colorectal and hepatocellular
carcinomas [45, 46]. SMYD4 was identified as a potential tumor suppressor involved in breast
cancer [47]. Expression of SMYD4 partially inhibits the expression of PDGFα and the lack of
SMYD4 promotes PDGFα production [47]. The Drosophila melanogaster homolog of SMYD4
was found to recruit the HDAC co-repressor complex and thereby aid in fly development [48]. Eri
is another component of the HDAC co-repressor complex, which interacts with SMYD4 [48].
SMYD5 is known to associate with the NCoR co-repressor complex and regulate proinflammation genes through trimethylation of H4K20 [15]. In macrophages, the SMYD5–NCoR
co-repressor complex was found to repress the expression of toll-like receptor 4 (TLR4) genes
[15].
SMYD proteins methylate several non-histone targets. In the cell cycle, SMYD2
methylates p53 and retinoblastoma tumor suppressor (RB) [3, 49, 50]. p53 methylation by SMYD2
reduces the transactivation activity of p53 [3]. In esophageal squamous cell carcinoma (ESCC),
p53 methylation and inactivation were associated with aberrant oncogenic expression of SMYD2
[16]. Additionally, SMYD2 has an anti-apoptotic effect when it methylates p53 in cardioblasts
[51]. RB methylation at Lys860 is regulated during cell cycle progression and cellular
differentiation [49, 50]. It has been shown that RB methylation binds to the transcriptional
repressor L3MBTL1 causing repression of E2F target genes [49]. In response to DNA damage,
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SMYD2 was also found to methylate PARP1 at lysine 528, and this methylation regulates the
PARP1’s poly(ADP-ribosyl)ation activity in HeLa cells [52]. In intracellular signaling, SMYD3
targets two important kinases for methylation: MAP3K2 and vascular endothelial growth factor
receptor-1 (VEGFR1). Methylation of MAP3K2 prevents PP2A phosphatase, a key negative
regulator of the MAP kinase pathway, from binding to MAP3K2 [5]. Methylated MAP3K2 links
SMYD3 to Ras-driven cancer promoting cell proliferation and tumorigenesis [5]. VEGFR1
methylation by SMYD3 augments VEGRF1 kinase activity, which is thought to enhance
carcinogenesis [53]. Since SMYD3 is primarily found in the cytoplasm during G0–G1 arrest, it is
thought that SMYD3 enhances VEGFR1 signaling when cells are at the resting state [53].
Current data have shown that SMYD proteins methylate a variety of histone and nonhistone targets which contribute to their various roles in cell regulation including chromatin
remodeling, transcription, signal transduction, and cell cycle control. In order to better understand
how SMYD proteins interact with such an extensive yet specific range of targets, structural
examination of the SMYD family has provided significant insight to the diversity of SMYD
binding and function. This review will provide a thorough description of SMYD structure and
function and serve to inform rational drug design process targeting this cancer-related protein
family.
SMYD Structure and Function
2.1. Overall SMYD Structure
Crystal structures of SMYD1, SMYD2, and SMYD3 with cofactors are currently
available[24, 35, 39, 54-56]. Additionally, SMYD2 structures were solved with the estrogen
receptor α (ERα) and p53 peptides enabling us to investigate the different interactions made
between the two different substrates [54, 57, 58]. In all of the available SMYD structures, SMYD
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proteins share a homologous bilobal structure separated by a non-conserved primary sequence of
variable length (Figure 1B). The N-terminal lobe is divided into four domains: SET, MYND, SETI, and post-SET. The catalytic SET domain is located in the middle of the N-terminal lobe in
proximity to the C-terminal lobe. The C-terminal lobe is organized into helices that were found to
be orientated in open or closed conformations [24, 35, 39]. SMYD1 has the most open structure
and SMYD3 has the most closed one. SMYD2 is a conformational intermediate between SMYD1
and SMYD3 (Figure 1C). The difference in the relative positions of the N- and C-terminal lobes
creates different shapes for substrate binding. The structure of SMYD1 resembles an open-ended
“wrench” with two lobes separated by gap. Unlike SMYD1, SMYD2 and SMYD3 form a
clamshell like structure due to the absence of the C-terminal protruding helix.
Currently, there are no structural data for SMYD4 and SMYD5. While SMYD1–3 share
well aligned domains, SMYD4 and SMYD5 are vastly different in their primary sequence (Figure
1A). SMYD4 contains an additional TPR domain before the N-terminal lobe, and the CTD is far
extended. SMYD5 completely lacks the CTD, yet the molecular size of SMYD5 is close to
SMYD2 and SMYD3. Functional implications of the differences in SMYD4 and SMYD5 are
unknown, but structural data of SMYD4 and SMYD5 are of interest to address these questions.
2.2. SET, the Evolutionary Conserved Methyltransferase Domain
The SET domain is split by the MYND domain into two sections: the S-sequence and the
core SET domain (Figure 1A). The S-sequence is a small region that may aid in cofactor binding
or protein–protein interaction along with its adjacent domain, MYND [7, 35]. The topology of the
catalytic SET domain is well conserved between SMYD1–3, which is essentially similar to other
traditional SET proteins despite the split in the primary sequence by the MYND domain [35]. SET
domain often co-exists with post-SET, SET-I, and pre-SET, and together they contribute to
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Figure 1. Overall structure of SET and MYND domain-containing proteins (SMYD)
(A) Domain diagram of SMYD protein family. S, S-sequence; MYND (Myeloid, Nervy, DEAF1);
SET-I, insertion SET (Su(Var)3-9, Enhancer-of-zeste, Trithorax) domain; (S)ET, core SET
domain; Post-SET, SET C-terminal flanking domain; CTD, C-terminal domain; (B) Ribbon
diagram of SMYD1 (PDB code: 3N71), SMYD2 (PDB code: 3QWV and 3QWW), and SMYD3
(PDB code: 3PDN). The S-sequence, MYND, SET-I, core SET, post-SET, and CTD are depicted
in light green, blue, pink, green, cyan, and red. Secondary structures, α-helices and β-strands are
labeled and numbered according to their position in the sequence. Cofactors, sinefungin (SFG) and
S-adenosyl-L-homocysteine (SAH), are depicted in balls and sticks; and (C) Structural
superposition of SMYD proteins: SMYD1 (magenta), SMYD2 (SFG, cyan; SAH, green), and
SMYD3 (yellow). The superposition is based on the N-terminal lobe.
cofactor binding, substrate binding, or the structural stability of the protein [59-61]. In SMYD
proteins, the post-SET domain is made up of three α-helices bundled around a zinc atom
coordinated by four cysteine residues. The SET-I domain along with MYND is an insertion region
between the SET domain strands β5 and β8. Compared to other SET proteins like SET7 and Dim-
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5, this insertion region is 6–10 times larger in size in SMYD proteins [35]. The pre-SET domain
is often found in other SET containing proteins, but the pre-SET region is absent in SMYD1–3
proteins. Normally, this pre-SET region packs against an equivalent β-sheet made up of β4, β10,
and β11, but in SMYD proteins, this β-sheet interacts with residues from the CTD in the αM–αN
loop (Figure 1B). Interestingly, SMYD4 contains TPR repeats flanking the N-terminus of the Nterminal lobe (Figure 1A). This new region may introduce a pre-SET domain or add a third lobe
to the overall structure.
2.3. MYND, the Zinc Finger Motif
MYND domain is a zinc finger motif identified to bind to proline-rich regions serving as a
protein–protein interaction module [37, 38, 62]. In SMYD proteins, the MYND domain is part of
the N-terminal lobe that interacts with the catalytic SET domain, but it does not participate in
substrate or cofactor binding (Figure 1B) [35]. Consistently, deletion of the MYND domain does
not affect the methyltransferase activity of SMYD2 in vitro, suggesting that the MYND domain is
dispensable in methylation [41]. Despite the high sequence similarity to LIM (Lin11-Isl1-Mec3)
domains, the MYND domain exhibits a different type of fold. The secondary structure of the
MYND domain adopts a β–β–α topology, which is structurally similar to some PHD (Plant Homeo
Domain) and RING motifs (Figure 2A). Although the MYND domains from AML1/ETO and
SMYD proteins are only 30% identical in the primary sequence, the backbone and chelating zinc
centers of the MYND are well superimposed (Figure 2A). The two structures share two antiparallel β-strands (β6 and β7) and a small kinked α-helix (αA) that organize around two zinc atoms.
Seven cysteine residues and one histidine are centered around the two zinc ions in a C4C2HC
arrangement.
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Figure 2. Structure of MYND domains
(A) Structural superposition of the MYND domains of SMYD and AML1/ETO (PDB code:
2ODD). MYND is represented by ribbon and colored in magenta (SMYD1), cyan (SMYD2),
yellow (SMYD3), and blue (AML1/ETO). Proline-rich peptide bound to AML1/ETO is depicted
by ribbon; (B) Superposition of the peptide binding pockets. Putative peptide interacting residues
are colored according to the scheme in (A). The proline-rich peptide bound to AML1/ETO is
depicted by balls-and-sticks; and (C) Surface representation of the MYND domains. Coloring is
according to the electrostatic potential: red, white, and blue correspond to negative, neutral, and
positive potential, respectively. The vacuum electrostatics/protein contact potential was generated
by PyMOL. The proline-rich peptide, represented by balls-and-sticks, is modeled by superposition
of the MYND domain of SMYD and AML1/ETO.
The MYND domain from AML1/ETO is known to bind to a PPPLI motif, and in SMYD1
and SMYD2, the MYND domain can interact with proteins with a similar proline-rich sequence
[7, 37, 63]. SMYD1 binds to the muscle-specific transcription factor skNAC via a PPLIP motif
[7]. In a previous yeast two-hybrid study, SMYD2 was found to interact with five different proteins
possessing a PXLXP motif [63]. To date, a MYND-binding partner for SMYD3 has not been
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identified, but the MYND structural similarities certainly suggest a proline-rich peptide-binding
site for SMYD3. Three conserved and highly superimposed residues in SMYD3 (Trp80, Gln76,
Tyr70) and in SMYD1–2 (Trp83, Gln79, Tyr73) may contribute to the binding of the proline-rich
peptide (PXLXP) (Figure 2B). The tryptophan residue may pack against the first proline (P1), and
the remaining glutamine and tyrosine residues may form a hydrophobic pocket for leucine (P3) to
bind. The S-sequence in SMYD1 is also involved in binding to the skNAC proline-rich peptide
[7], suggesting that regions other than the MYND domain may also play a role in determining
binding specificity.
Electrostatic surface analysis shows the MYND domain is highly positively charged in
SMYD1–3 (Figure 2C). This positively charged surface likely contributes to a protein–DNA
interaction. SMYD binding to DNA was first identified in SMYD3, and binding to a specific DNA
motif, 5'-CCCTCC-3', was found to regulate transcription of SMYD3 target genes such as Nkx2.8
[4]. Mutation of Arg66 within the MYND domain disrupted DNA binding of SMYD3 and
abolished a DNA-induced increase in SMYD3 methyltransferase activity [64]. Interestingly,
Arg66 appears to superimpose with similar conserved Lys69 in both SMYD1 and SMYD2, and
the positively charged surface across the MYND domain is well observed across SMYD1–3
(Figure 2C). This certainly suggests that SMYD1 and SMYD2 are also involved in DNA binding.
A recent study shows that SMYD2 binds to the promoter region of TACC2 and regulates TACC2
expression at a site different from the binding site for SMYD3 [41].
The exact nature of DNA binding in SMYD proteins is unknown, and how DNA binding
affects the activity of SMYD proteins is yet to be identified. Structural studies of SMYD–DNA
complexes are of interest to address these questions. Additionally, the overlap of the positively
charged surface and proline-rich peptide-binding site in the MYND domain (Figure 2C) raises
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intriguing questions regarding whether the peptide and DNA binding are mutually exclusive and
what are the functional roles of such a scenario in the context of transcriptional regulation. In many
cases, binding of SMYD3 to the promoter region of its target genes is associated with both H3K4
trimethylation and gene activation [44, 65-67]. Surprisingly, SMYD3 shows virtually no activity
towards H3K4 in vitro compared to other targets such as H4K5 or MAP3K2 [5, 68]. This
inconsistency suggests that DNA binding may induce a conformational change in SMYD3 that
may subsequently affect substrate binding and specificity. Such a model remains to be determined,
but the ability of SMYD2 to undergo a conformational change that alters the shape of the substratebinding site provides a rationalization for this possibility [24].
2.4. Cofactor Binding Pocket
The SET-I, SET, and post-SET domains create a deep surface pocket allowing the Lshaped cofactors, S-adenosyl-L-homocysteine (SAH) and sinefungin (SFG) to bind (Figure 3A).
Several cofactor and pocket interactions are shared among the SMYD family (Figure 3B). The
adenine moiety of SAH or SFG is sandwiched between a conserved benzyl phenylalanine and
aliphatic lysine or arginine side chain. The purine atoms N6 and N7 form a hydrogen bond to the
carboxyl and amide groups of a conserved histidine residue, but the ribose hydroxyl groups form
hydrogen bonds with somewhat similar neighboring residues among the SMYD family. At the
positively charged amino group, a similar triangular array of hydrogen bonds is formed with the
carbonyl oxygens from arginine and lysine (asparagine in SMYD3) and the amide Oδ from a
separate asparagine. In the middle of cofactors, two backbone carbonyls and the side chain oxygens
from conserved tyrosine and asparagine surround the Sδ atom in SAH or the C–NH2 amine group
in sinefungin. The C–NH2 amine group of sinefungin corresponds to the S–CH3 sulfonium group
in S-adenosyl-L-methionine (SAM). Some of the aforementioned surrounding oxygens are
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Figure 3. Cofactor binding pocket
(A) Surface representation of the cofactor-binding pocket of SMYD1–3, SET7 (PDB code: 1O9S),
and Dim-5 (PDB code: 1PEG). The surface of SMYD proteins is colored according to domains.
Bound SAH or SFG is depicted by sticks with the carbon atoms colored in white; (B) Superposition
of the cofactor binding sites. SMYD residues are represented by sticks with the carbon atoms
colored according to the scheme in Figure 1C. Cofactor is depicted by balls-and-sticks overlaid
with translucent molecular surface.
responsible for hydrogen bonding with the C–NH2 amine group in sinefungin, and the same
interaction is thought to contribute to destabilizing the active methyl group during enzymatic
methylation [35, 58].
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Large differences were observed at the carboxylate moiety of cofactors. In SMYD1–2, the
carboxylate moiety is stabilized by a salt-bridge interaction with an arginine guanido group, but in
SMYD3, this electrostatic interaction is substituted by a hydrogen bond to a tyrosine residue from
a non-equivalent location (Figure 3B). This hydrogen bonding in SMYD3 represents an unusual
variation, as the replaced electrostatic interaction is present in most SET containing proteins [24,
35, 69, 70]. As a result, the cofactor binding sites of SMYD1 and SMYD2 are more similar to one
another than they are to the SMYD3 structure. However, all SMYD proteins have a nearly buried
cofactor-binding site compared to SET7 and Dim-5. The bound cofactors share similar interactions
in these proteins, but the large SET-I domain of SMYD proteins creates a nearly buried cofactor
conformation (Figure 3A). This buried cofactor conformation, however, does not affect the
enzymatic activity of SMYD1. Mutation of the SET-I residues responsible for the buried
conformation only had modest effects on H3K4 methylation activity [35]. However, mutation of
the S-sequence residues responsible for the adenine moiety binding completely abolished the
enzymatic activity [35]. This suggests that the split S-sequence is an integral part of the SET
domain contributing to cofactor binding.
2.5. Substrate Peptide Binding Site
To date, there are two SMYD–substrate complex structures available, SMYD2–ERα and
SMYD2–p53 [54, 57, 58]. These structures have provided significant insight into the substrate
binding and broad substrate specificity of the SMYD family. The ERα and p53 peptides bind to
SMYD2 in a U-shape conformation (Figure 4A). The peptides are clamped between the N- and Cterminal lobes with the target lysine inserted into the lysine access channel. Residues contributing
to peptide binding mainly come from the β8–β9 hairpin and a loop preceding the post-SET domain.
The structure and residues at the turn of the β-hairpin vary significantly among the SMYD family,
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Figure 4. Substrate binding site
(A) Surface representation of SMYD2 substrate binding site. The surface is colored according to
domains. ERα and p53 peptides are depicted by ribbons and colored in yellow and blue
respectively; (B) Superposition of the substrate binding clefts. SMYD residues are represented by
ribbons and colored according to the scheme in Figure 1C. ERα peptide is shown in balls-andsticks colored in green; (C) Surface representation of the substrate-binding site of SMYD1 and
SMYD3. The ERα peptide, represented by sticks, is modeled by superposition with the N-terminal
lobe of SMYD2; and (D) Superposition of the SMYD2-bound ERα (yellow; PDB code: 4O6F)
and p53 peptides (light blue; PDB code: 3TG5). Position 0 refers to the target lysine. Detailed
structural and binding differences at position +3 and +5 are shown in callout boxes. Peptideinteracting SMYD2 residues are colored according to domains.
but in SMYD2 this region is important for substrate recognition (Figure 4B). This suggests that
the structural features of the β8–β9 hairpin may contribute to the different substrate specificity of
SMYD proteins. Additionally, the C-terminal domain of SMYD2 is directly involved in ERα and
p53 binding, but the different CTD conformation in SMYD1 and SMYD3 implies a substantially
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different substrate-binding mode in order to adapt to different substrate binding pockets (Figure
4C). The CTD conformation in SMYD proteins correlates with the size of the substrate-binding
pocket, which may thereby provide another level of substrate specificity. Interestingly, SMYD3
appears to prefer smaller sized substrates and its methyltransferase activity is significantly higher
for H4K5 and MAP3K2 than H4K5 [5, 68]. This is likely due to the small glycine residues
neighboring the target lysine in H4K5 and MAP3K2. The smallest and most flexible amino acid,
glycine, may facilitate substrate access to the closed active site of SMYD3 (Figure 4C).
Comparison of the SMYD2–ERα and SMYD2–p53 structures has provided insight into the
broad substrate specificity of SMYD2 [57]. SMYD2 is able to methylate several targets and the
structural basis of this broad substrate specificity lies in the presence of multiple substrate-binding
sites in SMYD2 structure [54, 57, 58]. The structural comparison shows that the liganded SMYD2
structures are well superimposed with an RMSD value of 0.6 Å out of 430 Cα atoms [57]. The
ERα and p53 peptides have a similar U-shape conformation and are well superimposed at positions
−1, 0, +1, and +2 (position 0 referring to the target lysine) (Figure 4D). Large deviations are found
in the peptides extending out of the U-base. For example, different interactions are seen at positions
+3 and +5 between the ERα and p53 peptides (Figure, 4D). Arg+3 and Arg+5 in the ERα peptide
binds to the β8–β9 region in the SET domain. In the p53 peptide, Lys+3 interacts with Tyr370,
Tyr374, and Asp242, and the Gln+5 chain is inserted into a pocket formed by His341, Tyr344,
Gln345, Tyr370, Leu244, and Tyr245. The two different peptide conformations and the broad
substrate binding space inside SMYD2 present plausible explanations for the multiple
accommodations for SMYD2 and substrate binding. Structural study of additional SMYD2–
substrate complexes may be necessary to corroborate this model. Because of the sequence diversity
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Figure 5. Target lysine access channel
(A) Surface representation of overall SMYD2–ERα structure. ERα peptide, SAH, and target lysine
are indicated; (B) Superposition of the lysine access channels. SMYD residues are represented by
sticks with the carbon atoms colored according to the scheme in Figure 1C. Target lysine is colored
in white; and (C) Surface representation of the lysine access channel of SMYD1–3, SET7, and
Dim-5. SAH or SFG is depicted by sticks with the carbon atoms colored in white.
of SMYD2 substrates [57], the new SMYD2–substrate complex structures could potentially lead
to the identification of novel substrate binding modes.
2.6. Target Lysine Access Channel
In SET domain-containing enzymes, the lysine targeted for methylation fits into a
hydrophobic pocket called the target lysine access channel (Figure 5A). The lysine access channel
in SMYD proteins has a well-superimposed backbone and consists of a hydrophobic core
surrounding the hydrophobic portion of the targeted lysine (Figure 5B). A highly conserved
tyrosine residue preceding the post-SET domain is found in all SET classes including SMYD1
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(Tyr252), SMYD2 (Tyr240), and SMYD3 (Tyr239). The tyrosine side chain appears to orient the
target lysine into the channel, and substitution of this residue to phenylalanine completely
abolished the enzymatic activity of SMYD2 and SMYD3 [2, 55, 71]. Seven residues are important
for creating the lysine crevice, and of the seven, only three are aromatic residues. Two tyrosines
and one phenylalanine are well conserved among SMYD1–3 with the exception of the orientation
of phenylalanine in SMYD1. The aromatic ring is rotated about 110° around the Cα–Cβ bond axis
which is pointed away from the lysine access channel; therefore, SMYD2 and SMYD3 have a
well-defined and tighter channel than SMYD1 (Figure 5C). The other three small and nonaromatic residues are fairly conserved and responsible for creating a more open channel in
comparison to SET7 and Dim-5 [35].
A more open channel may accommodate a larger substrate or is susceptible to ligandinduced conformational changes. It may also contribute to the broad and weak substrate binding
especially for H3K4 methylation. This weak binding appears to be largely contributed to the
substitution of large aromatic residues to smaller hydrophobic side chains such as valine, leucine,
and isoleucine [35]. For example, substitution of Val214 to tyrosine in SMYD1 created a tighter
access pocket, and thereby the binding of SMYD1 and H3 peptide significantly increased
presumably due to a more compact channel and the additional hydrogen bond between the tyrosine
hydroxyl group and an ε-amino from the neighboring lysine side chain [35]. This gain-of-function
mutation indicates that a well-defined channel is important for securing the target lysine in the
active site. A ligand-induced conformational change in the lysine access channel may be required
for SMYD1 to efficiently methylate a substrate. In order to address these questions, it is of interest
to determine a SMYD1 structure in complex with a substrate.
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2.7. TPR-Like C-Terminal Domain
The CTD domain of SMYD proteins contains a series of antiparallel α-helices that display
a similar structure to TPR domains despite the lack of sequence identity (Figure 1B). TPR domains
are important for binding of cochaperones to Hsp90. For example, the Hop1 TPR domain binds to
the very C-terminal end of Hsp90 mediating Hsp90 chaperone activity (Figure 6A) [72, 73]. The
CTD structure is also well conserved in the SMYD family, and the only chief difference is the
extended and protruded αN helix that resembles the “handle” of the wrench-shaped SMYD1
(Figure 6A). This feature is unique to SMYD1, as SMYD2–3 with the shorter αN helix resemble
the shape of a clam-like shell. The unique portion of the αN helix in SMYD1 is well conserved
from fish to human (data not shown). This region contains a patch of hydrophobic residues that
mediate the crystal packing in SMYD1 crystals (Figure 6B). Interestingly, the CTD structure of
SMYD1 is similar to the TPR structure of FKBP52 (Figure 6C). In FKBP52, the TPR domain also
has a protruding C-terminal helix that contains a putative binding site for calmodulin [74, 75]. The
function of the unique SMYD1 C-terminal helical tail is unknown, but the conserved sequence and
involvement in the crystal packing suggests that it may serve as a site for protein–protein
interaction.
The structural orientation of the CTD varies significantly among the SMYD family (Figure
1C). SMYD1 has an open CTD conformation with the substrate-binding cleft completely exposed
in the protein. In SMYD3, the CTD conformation is closed as the significant contact between the
N- and C-terminal lobes creates a narrower opening to the substrate-binding pocket [39]. SMYD2
is like a conformational intermediate between SMYD1 and SMYD3. Additionally, the CTD
domain of SMYD2 is flexible and can undergo a conformational change when different cofactors
bind [24]. The CTD conformational change results in two SMYD2 structures with a slight
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Figure 6. TPR-like C-terminal domain (CTD)
(A) Structural superposition of the CTD domains of SMYD and TPR domain of Hop1 (PDB code:
1ELR). SMYD proteins are represented by ribbons and colored according to the scheme in Figure
1C. The Hop1 TPR domain is shown in blue. Hsp90 peptide bound to Hop1 is depicted by ballsand-sticks; (B) Crystal lattice of SMYD1 shows the involvement of the protruding C-terminal αhelix in the crystal packing; and (C) Structural superposition of the CTD domain of SMYD1 and
TPR domain of FKBP52 (PDB code: 1QZ2). SMYD1 is colored in purple and FKBP52 in white.
difference in the size and shape of the substrate-binding pocket [24]. Therefore, the orientation of
the CTD domain may affect substrate specificity, and different pocket shapes and sizes may be
involved in modulating the substrate preference of SMYD proteins. In addition, the CTD flexibility
of SMYD2 suggests that SMYD2 may have the ability to adapt to substrates with different sizes,
implying broad substrate specificity. Interestingly, SMYD2 so far has the broadest substrate
specificity among SMYD proteins [57].
The CTD domain appears to play dual roles in substrate binding. Deletion of the CTD from
SMYD1 results in increased binding and methylation on histone H3 suggesting that the CTD may
have steric effects controlling substrate access to the active site [35]. In SMYD2, the CTD plays
an important role in substrate recognition and binding, but the actual effect of the CTD appears to
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be substrate-dependent. The CTD deletion has no effect on methylation of p53 peptide and histone
H3 protein, but it results in a significant increase in H3K4 peptide methylation and significant
decrease in p53 protein methylation [58]. Although these results seem paradoxical, the differential
CTD effects have proved its complex roles in substrate recognition and binding. In addition, the
TPR-like structure of the CTD suggests a potential role for the CTD in modulating protein–protein
interaction. The predicted peptide-binding site in the CTD is located at the inner surface of the
CTD in close proximity to the substrate-binding pocket (Figure 6A) [24, 57]. Binding to this
location could therefore affect the substrate binding and enzymatic activity. Interestingly, the
activity of SMYD proteins can be significantly increased in the presence of Hsp90 [4, 41, 42]. In
the case of SMYD2, Hsp90 not only enhances the activity but also changes the substrate preference
from H3K36 to H3K4 [41]. The questions remain whether Hsp90 regulates SMYD function via
binding to the CTD domain and whether such binding has a reciprocal effect on Hsp90 chaperone
activity. Nonetheless, the close proximity to the active site and flexibility and multi-orientations
of the CTD suggest that it is a bona fide regulatory motif in SMYD proteins.
2.8. Additional Substrate Binding Site?
The polyethylene glycol (PEG)-binding site found in the SMYD2–ERα structure has
suggested additional and extended substrate-binding pockets (Figure 7A) [57]. PEG binding was
also found in other protein structures, and in most cases, PEG binding has important functional
implications mimicking ligand binding in proteins [76-78]. In SMYD2, the PEG molecule
primarily binds to the CTD domain with an omega-turn conformation with one end found near the
surface groove shaped by αH, αI, and αJ and the other end extended between αK and αL helices
(Figure 7B). The residues responsible for contributing PEG binding include Lys309, Tyr344,
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Figure 7. Additional substrate binding site
(A) Surface representation of the PEG binding site in SMYD2. PEG is depicted by sticks with the
carbon atoms colored in purple. ERα peptide is displayed as ribbon and colored yellow; (B)
Putative PEG interacting residues. SMYD2 residues are colored according to domains. ERα
residues are shown in yellow. PEG is represented in the same way as in (A); and (C) Comparison
of the binding sites of ERα (yellow), p53 (blue), PEG (purple), Hsp90 (light blue), and a ribosomal
peptide (orange). The ribosomal peptide is overlaid with 2Fo−Fc omit map calculated at 2.8 Å and
contoured at 1.5σ. The Hsp90 peptide is modeled by superposition of the SMYD2 CTD and Hop1
TPR.
Gln345, Gly348, Leu351, Tyr352, Trp356, and Lys387 from the CTD and Glu190 from the SET
domain. The ERα peptide may also interact and stabilize PEG binding due to its close proximity
to Arg+3. Note that all of the residues participating in PEG binding (except for Lys309) are not
conserved in the SMYD family, which indicates a possible SMYD2-specific binding site.
The PEG binding site overlaps the predicted Hsp90 binding site (Figure 7C), suggesting
that the PEG binding site might possess the peptide or substrate binding potential. This notion is
supported by the SMYD2 structure binding to a ribosomal peptide (unpublished data). Instead of
forming a U-shape formed by the ERα and p53 peptides, the ribosomal peptide density creates a
partial U-shape at the ERα or p53-binding pocket, but the N-terminal end extends out through the
αH/αI/αJ-binding groove of the PEG molecule (Figure 7C). This new mode of binding is vastly
different to the ERα and p53 peptides and the orientations of the peptides are completely reversed.
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This demonstrates the exceptional substrate adaptability of SMYD2, and the multiple binding sites
and that some of these binding sites may be substrate-specific have provided explanations for its
broad substrate specificity. It is of interest to reveal whether the αK/αL-binding groove of the PEG
molecule in SMYD2 also indicate an additional substrate-binding pocket. Further investigation
into different peptide binding and conformations are necessary to better characterize the diversity
of SMYD structure and function.
Drug Design Perspective
SMYD proteins provide a new avenue for cancer and cardiovascular treatment.
Overexpression of several of SMYD proteins is associated with nearly all cancer types[5, 16, 17,
50, 65]. Overexpression of SMYD1 represses transcription of genes necessary to produce ion
channels in the heart, and repression of ion channel expression causes heart failure [79]. SMYD1
overexpression was also found in hypoplastic left heart syndrome (HLHS), a disorder
characterized by the severely underdeveloped left ventricle [80]. SMYD2 is overexpressed in
ESCC or p53-related cancers, and knockdown of SMYD2 inhibits tumor cell proliferation [16-18,
50]. SMYD3 is overexpressed in more than 14 types of cancers such as breast cancer, colon cancer,
prostate cancer, lung cancer, and pancreatic cancer [4, 20, 21, 65, 81-88]. SMYD3 overexpression
often correlates with poor prognosis, and knockdown of SMYD3 proved to inhibit tumor growth
[4, 84-89]. Therefore, drug intervention of any of SMYD proteins may be beneficial to the fields
of cardiovascular disease and cancer.
Efforts to create SMYD inhibitors are currently underway. AZ505 is a potent SMYD2
competitive inhibitor recently identified from a high throughput chemical screening [54]. In the
crystal structure, AZ505 bound to the lysine access channel, and ITC analysis indicated inhibitor
binding is primarily driven by hydrophobic interactions providing a low KD ~0.5 μM (Figure
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Figure 8. AZ505-bound SMYD2 structure
(A) Interactions between AZ505 and SMYD2. AZ505 is depicted by balls-and-sticks with the
carbon atoms colored in white. SMYD2 residues are depicted by sticks colored according to
domains; (B) Comparison of the binding sites of ERα, p53, and AZ505. The ERα and p53 peptides
are depicted by sticks and colored in yellow and blue. AZ505 is represented in the same way as in
(A); and (C) Surface representation of SMYD2–ERα structure illustrates potential drug targeting
sites: ERα (yellow), p53 (blue), PEG (purple), Hsp90 (light blue), the ribosomal peptide (orange),
and proline-rich peptide (hot pink). SAH and AZ505 are depicted by sticks.
8A)[54]. The three moieties of AZ505 have similar interactions found in the p53 and ERα peptides.
The benzooxazinone group is packaged into the lysine channel where several hydrophobic and
electrostatic interactions are made (Figure 8A). The cyclohexyl and dichlorophenethyl groups
adopt the same −1 and −2 position, but they appear more compact to the surface than the p53 and
ERα peptides (Figure 8B). In addition, the Gly183 carbonyl oxygen forms a similar hydrogen bond
to the amide linker between the benzooxazinone and cyclohexyl groups. Therefore, the potency of
AZ505 appears to be due to a complete blockage of the core region of the SMYD2 active site and
preventing it from binding to the target lysine.
Therapeutic drug intervention of SMYD proteins may not be limited to inhibiting the lysine
access channel. SMYD2 is necessary for methylating many targets and is involved in various
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functionally independent cellular processes [57]. Complete knockdown of SMYD2 may not be a
viable option since unselective SMYD2 inhibition may cause undesirable and perhaps lethal side
effects. In order to selectively design a therapeutic drug to inhibit SMYD2 function in the context
of cancer, one may consider targeting alternative binding sites for inhibition that will interfere with
only a subset population of SMYD2. For example, designing a drug that will mimic the binding
properties of the p53 peptide may provide specificity to oncogenic SMYD2 function in p53-related
cancers. Targeting the binding properties of the ERα peptide may be beneficial to aggressive ERαnegative breast tumors by specifically restoring functional ERα expression [71]. The PEG or
ribosomal binding site may also provide a genuine substrate-specific targeting option without the
fear of interference with binding of the p53 and ERα peptides. Targeting MYND-mediated protein
interactions may be another viable approach in cancer therapy as binding of the MYND to the
proline-rich sequences of the tumor suppressor EBP41L3 links SMYD2 to meningiomas and lung
cancer [41, 90, 91]. Finally, the CTD orientations related to the sizes and shapes of the SMYD
substrate-binding pockets raise a possibility for selective drug design for different members of the
SMYD family. Challenges remain because of the potential conformational flexibility of the CTD
domain of SMYD proteins. Selective and potent drug design will require the consideration of
conformational changes in SMYD proteins and understanding of the functional role of each
conformational state. Further investigation into the structural differences between SMYD proteins
will be necessary to distinguish specificity and efficacy into the drug design process.
Concluding Remarks
SMYD proteins are an exciting field of study as they are linked to many types of cancer-related
pathways. Cardiac and skeletal muscle development and function also depend on SMYD proteins
opening a possible avenue for cardiac-related treatment. The purpose of this review is to gather
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current structural data to support the versatile roles of SMYD proteins. We provide a summary of
the structures of the SMYD family focusing on their structural differences. The structures of the
individual domains in SMYD1–3 are similar but the orientations of the CTD are substantially
different resulting in open or closed conformations. Different CTD conformations suggest that
SMYD proteins could undergo a conformational change that offers dynamics for regulation of
substrate specificity [24, 35, 39]. SMYD2 conformations are sensitive to cofactor binding which
alters the size of the substrate-binding pocket [24]. It is conceivable that the methyltransferase
activity of SMYD proteins may be regulated by controlling lobe conformation and dynamics like
some kinases [92, 93]. SMYD structures have a potential for efficacious drug intervention, but
efforts to design a drug should not be limited to the target lysine access channel. Analysis of SMYD
structures revealed many other binding sites with drug targeting potential, such as the broad
substrate-binding pocket, PEG and ribosomal binding site, proline-rich peptide binding site, and a
yet-unidentified DNA binding groove (Figure 8C). With the different binding sites and
conformations, it is possible to effectively knockdown cancerous function of SMYD proteins such
as SMYD2 and SMYD3 without disrupting the entire functional population of SMYD proteins.
Additionally, analysis of current structures raised many new questions. The unique protruding Cterminal helix of SMYD1 may be involved in protein–protein interaction. The CTD orientation
may determine substrate specificity. How DNA binding alters SMYD3 structure and function
remains to be determined. Whether the possible binding of Hsp90 to the CTD provides a
mechanism for SMYD activity enhancement and the potential role of this coplay in cancer and
heart development are also unclear. In summary, SMYD proteins are of functional and therapeutic
importance, and continued elucidation of their structural differences and substrate specificity will
lead to additional functional implications.
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CHAPTER 2 NEW OPEN CONFORMATION OF SMYD3 IMPLICATES
CONFORMATIONAL SELECTION AND ALLOSTERY
*Published in AIMS Biophys. 2017;4(1):1-18. doi: 10.3934/biophy.2017.1.1. Epub 2016 Dec 20.
All authors agreed with including their work in this dissertation.
Introduction
SMYD3 belongs to a special class of protein lysine methyltransferases containing SET and
MYND domains [94]. The SET is a catalytic motif responsible for lysine methylation. The MYND
is a protein-protein interaction module involved in transcriptional cofactor recruitment. SMYD3
is overexpressed in more than 15 types of cancers such as breast cancer, colon cancer, prostate
cancer, lung cancer and pancreatic cancer [4, 5, 94, 95]. Overexpression of SMYD3 often
correlates with poor prognosis and its knockdown inhibits tumor growth [4, 5, 95]. Therefore, drug
intervention of SMYD3 may be beneficial to the fields of cancer. SMYD3 is involved in
tumorigenesis through methylation of histone and non- histone proteins. Histone methylation
regulates gene expression and methylation of non- histone proteins can impact biochemical and
cellular functions of the targets [5, 94, 95]. SMYD3 may directly or indirectly methylate histone
H3K4, H4K20 and H4K5 [4, 68, 96]. Through these methylations, SMYD3 is involved in tumor
cell viability, adhesion, migration and invasion. SMYD3 upregulates multiple cancer genes
through H3K4 trimethylation. These include the telomerase reverse transcriptase (TERT),
oncogenic c-Met, matrix metalloproteinase 9 (MMP-9), androgen receptor, myosin regulatory
light chain 9 (MYL9) and retinoblastoma protein-interacting zinc finger gene 1 (RIZ1)[12, 44, 53,
65, 94, 97]. SMYD3 targets Cyclin D2 through H4K20 trimethylation and contributes to a more
aggressive phenotype of prostate cancer [96]. H4K5 methylation by SMYD3 provides a potential
new link between chromatin dynamics and neoplastic disease [68]. SMYD3 methylates three nonhistone proteins: MAP3K2, vascular endothelial growth factor receptor-1 (VEGFR1) and AKT1.
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Methylation of MAP3K2 prevents PP2A phosphatase, a key negative regulator of the MAP kinase
pathway, from binding to MAP3K2 [5]. Methylated MAP3K2 links SMYD3 to Ras- driven cancer
promoting cell proliferation and tumorigenesis [5]. VEGFR1 methylation by SMYD3 augments
VEGRF1 kinase activity, which is thought to enhance carcinogenesis [53]. Methylation of AKT1
at lysine 14 is essential for AKT1 activation [98]. In addition, SMYD3 was found to promote
formation of inducible regulatory T cells and may be involved in reducing autoimmunity [13, 99].
SMYD3 in vitro methyltransferase activity is not fully consistent with its cellular activity. SMYD3
only weakly methylates H3K4 in vitro but its cellular methyltransferase activity has been
associated with H3K4 trimethylation at many genes [4, 5]. This functional inconsistency has
hindered further understanding of the role of SMYD3 in epigenetic gene regulation [68, 100].
However, poor in vitro activity can be partly explained by the crystal structures [39]. SMYD3 has
a closed conformation and a direct lobe-lobe interaction forms a cap over the substrate-binding
site. Though this cap structure does not prevent substrate binding, the resulting narrow opening to
the active site cavity could potentially affect the substrate binding competence of SMYD3 and
thereby the catalytic activity [101]. SMYD3 in vitro activity can be enhanced by Hsp90 and DNA
binding [4, 64]. The Hsp90 binding site has been mapped to a TPR-like C-terminal domain (CTD)
[102]. Due to the closed conformation, the predicted Hsp90 binding site is half-buried and
therefore the question remains how Hsp90 binds to SMYD3 and enhances its activity. The DNA
binding site was predicted to be located within the zinc-finger MYND domain [64]. However, this
domain is indispensable for SMYD enzymatic activities and how SMYD3 activity is regulated by
DNA binding remains a puzzle [94]. Here we present an open SMYD3 conformation and both
theoretical and experimental evidence that the conformational selection mechanism and allostery
may be involved in SMYD3 functional control.
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Materials and Methods
2.1 Molecular Dynamics Simulation
Molecular dynamics simulation was performed using NAMD [103]. Initial structure for
simulation was the crystal structure of human SMYD3–sinefungin complex (PDB code: 3PDN).
Prior to the simulation, this structure was modified by substituting the cofactor analog sinefungin
with cofactor S-adenosyl methionine (SAM or AdoMet). The substitution was based on the
structural comparison with the SMYD3–SAM complex (PDB code: 5CCL) and the two SMYD3
structures are very similar with a root-mean-squared-deviation (RMSD) of 0.6 Å. The resulting
system including the cofactor SAM was parameterized using CHARMM force field (version 36).
The net charge of the Zn ions in the structure was set to +2 and the chelating cysteine and histidine
residues were deprotonated. The system was solvated inside an orthorhombic box of water
molecules with a 13 Å padding in each direction. The system was then neutralized with NaCl at a
concentration of 0.15 M. The final system contained 69,749 atoms. Simulation was performed
with a 1 fs time step. Particle Mesh Ewald was used to treat long-range electrostatic interactions
and a cutoff of 12 Å was used for non-bonded interactions. Periodic Boundary Conditions were
applied during the simulation. The simulation was started with 2,000 steps of energy minimization.
The first half of the minimization had harmonic restraints on the protein and the second half
unrestrained minimization. The minimized structure was then slow heated from 0 to 300 K over
300 ps. At each integration step velocities were reassigned and the temperature was incremented
by 0.001 K. The heated structure was then equilibrated for 300 ps and velocities were rescaled to
300 K at every integration step. The system was further equilibrated using Langevin dynamics for
300 ps at constant temperature (300 K) and pressure (1 bar). The production run was performed in
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the NVE (microcanonical) ensemble at 300 K. The total simulation time was 50 ns and coordinates
were recorded every 1 ps.
2.2 Principle Component Analysis
Principal component (PC) analysis was performed using Bio3D [104]. The entire 50 ns
trajectory of 50,000 frames was used in the analysis. The overall translational and rotational
motions in the trajectory were eliminated by least squares fitting to the first frame. A 3 N × 3 N
covariance matrix was generated using Cartesian coordinates of Cα atoms. Diagonalization of the
covariance matrix generated 3 N eigenvectors, each having a corresponding eigenvalue. The
trajectory was projected onto a particular eigenvector to reveal concerted motions. Clustering of
the trajectory in the PC space was performed using k-means algorithm. k-means partitions the
observations into k clusters by minimizing the mean squared distance from each observation to its
nearest cluster center. The number of clusters was chosen based on the “elbow criteria”. At a
cluster count of two the BSS/TSS (Between-group Sum of Squares/Total Sum of Squares) ratio is
79.8%. The PC analysis- based free energy landscapes were produced by Carma [105]. The domain
motions along the PC axes were analyzed using the VMD plugin Hingefind [106].
2.3 Temporal analysis of structural attributes
Temporal changes of structural attributes including hydrogen bonds, salt-bridges, solvent
accessible surface area (SASA), Phi and Psi were analyzed using the VMD plugin Timeline [107].
Hydrogen bonds were calculated with a distance cutoff of 3.2 Å and angle cutoff of 20°. Saltbridges were calculated with a distance cutoff of 3.5 Å. SASA was calculated using a radius
extension of 1.4 Å. The calculations were performed every 25 ps.
2.4 Running cross correlation
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Residue-pair-wise cross-correlation coefficients were calculated with Bio3D. Running
cross correlation (RCC) was calculated using an in-house code. The first element of RCC was
obtained by taking the CC of the initial fixed subset of the trajectory. Then the subset was modified
by shifting forward: excluding the first frame of the original subset and including the next frame
following this subset in the trajectory. This created a new subset of frames, which was used to
calculate the next CC. This process was repeated over the entire trajectory. RCC was a plot of the
CC against the middle point of the CC time window. Inter- residue RCC deviation map was a heatmap of the standard deviation (σ) of residue-pair- wise RCC. σ was calculated for each RCC; the
heat-map represents the magnitude of σ.
2.5 Dynamic network analysis
Dynamical network analysis was done in VMD according to previous protocols[107, 108].
Each amino acid in the network was represented by one node and SAM by three nodes. Amino
acid nodes were centered on Cα atoms and SAM nodes were located at atoms Cα, C4’ and N9.
The edges between nodes were drawn if the residues were within a cutoff distance of 4.5 Å for at
least 75% of the trajectory. The edge distances were derived from pairwise correlations which
define the probability of information transfer across the edge. Correlations were calculated from
the trajectory by the program Carma [105]. The community substructure of the network was
obtained using the Girvan-Newman algorithm. Nodes in a community have more and stronger
connections within that community than the nodes in other communities.
2.6 Targeted molecular dynamics
Targeted molecular dynamics (TMD) simulation was performed with NAMD. The initial
and target structures used for simulation were the most dissimilar structures along the PC1 axis in
the full-trajectory PCA (see above). During simulation, all heavy atoms in the CTD were guided
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towards the final target structure by steering forces. The force on each atom was given by the
gradient of the potential: UTMD = 1⁄2 * k * (RMS(t)−RMS0(t))2, where RMS(t) was the
instantaneous best-fit RMS distance of the current coordinates from the target coordinates,
RMS0(t) was the preset RMSD value for the current time step and the force constant k was 200
kcal·mol−1·Å−2. Other simulation parameters were the same as those used in the above
conventional molecular dynamics simulation.
2.7 Protein Expression and purification
Human SMYD3 was essentially expressed and purified as previously described[39, 109]. In brief,
SMYD3 was cloned with a His6-SUMO tag in a pCDF-SUMO vector. Clones were inoculated in
LB media and grew until an OD600 reached 0.4–0.6. Cells were induced with 0.1 mM
isopropylthio-β-D-galactoside (IPTG) and grown overnight at 15 °C. Cells were harvested and
lysed using a French Press. Lysate was spun down and the supernatant was collected for
purification. The His6-SUMO-SMYD3 was captured with a Ni2+-affinity column and the His6SUMO tag was removed by yeast SUMO protease 1. Native protein was separated after running
through a second Ni2+ column. Finally, SMYD3 was further purified by a size exclusion column
in 20 mM Tris pH 8.0, 150 mM NaCl, 3% glycerol and 2 mM Tris(2-carboxyethyl) phosphine
(TCEP).
2.8 Small angle X-ray scattering
Small angle X-ray scattering (SAXS) data were collected at BioCAT beamline at Argonne
National Laboratory. Solution conditions were 20 mM Tris pH 8.0, 150 mM NaCl, 3% glycerol
and 2 mM TCEP. All measurements were made at 25 °C using a 100 μL capillary flow-cell.
Scattering data were collected at two SMYD3 concentrations: 1.2 and 7.7 mg/mL. Five frames
with a 1s exposure were taken and data were averaged and subtracted from averaged buffer frames.
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Low and high concentration data were merged based on an aligned middle q region to generate a
single scattering curve with a q range of 0.0042–0.39 Å−1. Radius of gyration (Rg) values were
calculated using the Guinier approximation [110]. The distribution function of interatomic
distances within SMYD3, P(r), was estimated from the scattering data using the GNOM algorithm
[110]. Ab initio dummy atom models were generated using DAMMIN [111]. Normal mode
analysis was carried out by SREFLEX [112]. Theoretical scattering curves of SMYD3 structures
were calculated with CRYSOL [110].
2.9 Statistical Analysis
Significance of mean differences for continuous data was evaluated by two-tailed t-test and
circular data (Phi and Psi) by Watson-Williams high concentration F test. Association between
continuous data was measured with Pearson correlation coefficient (r). Association of hydrogen
bonds and salt-bridges with conformational states were evaluated by PHI coefficient and
association of backbone angels or solvent accessible surface area by point- biserial correlation
coefficient. For backbone angles, sine values of angles were used in correlation analysis.
Results
3.1 Conformational transition from the closed to open states
Molecular dynamics (MD) simulation reveals a striking conformational transition of
SMYD3 from the closed to open states. The closed state is a crystal structure-like state
characterized by a direct lobe-lobe interaction at top of the substrate-binding site (Figure 1A). The
open state represents a previously-unidentified new conformational state which lacks the
equivalent interaction between the two lobes (Figure 1B). In the closed state, the lobe-lobe
interaction involves residues W300 from the C-lobe and S44, V47, V48, Q191 and V193 from the
N-lobe (Figure S1A). The interaction includes a hydrogen bond from W300 to S44 and
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Figure 9. New open conformation of SMYD3
(A) A closed-state and (B) open-state structure. SMYD3 is colored according to domain.
Secondary structures are labeled and numbered according to their position in the sequence. (C)
Principle component analysis (PCA) of full 50-ns trajectory. Left three, projection of the trajectory
onto the planes formed by the first three principle components. Conformers are colored according
to the k-means clustering. Rightmost, scree plot showing the proportion of variance against its
eigenvalue rank. (D) Visualization of the motions along PC1. Color scale from blue, green, to red
depicts low to high atomic displacements. (E) Superimposition of the open and closed states with
an SMYD3 bound peptide (MAP3K2, yellow) and inhibitor (EPZ031686, purple).
hydrophobic interaction of the W300 side chain with a pocket formed by the aforementioned Nlobe residues. The open state is characterized by the break of the direct lobe–lobe interaction. The
W300–S44 hydrogen bond breaks and the side chain of W300 flips out from the small hydrophobic
pocket. The substrate-binding site is widened and there is a clear gap between the N- and C-lobes.
As a result, the open state shows larger structural difference from the crystal structure (Figure
S1B).
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The conformational transition can be illustrated by the change in W300–S44 distance. In
the closed state W300–S44 maintains a hydrogen bonding distance for most of the time (Figure
S2A). In the open state the hydrogen bond breaks and their distance fluctuates between 4.9 Å and
21.2 Å. The distance shows a steep rise during the transition phase and the transition happens in
less than 0.3 ns. Therefore, the change in W300–S44 distance can clearly separate the two
conformational states. Covariance-based principal component analysis (PCA) further
demonstrates the presence of structure-distinct conformational states. The first PC axis alone is
sufficient to define two major clusters, one corresponding to the closed state and the other the open
state (Figure 1C). The two clusters are well separated along the PC1 axis and the boundary between
them is marked by low population of conformers (Figure S2B). This statistically indicates a freeenergy barrier for conformational transition. PC1 accounts for more than 50% of overall variance
and the motion described by PC1 is a clamshell-like motion between the N- and C-lobes (Figure
1D and S2C). The rotation axis of this motion passes between the two lobes lying at the bottom of
the gap between the two lobes. Therefore, this motion essentially depicts an open–closed dynamics
and the conformational transition between the closed and open states.
3.2 New open ligand-binding-capable conformational state
The new open state may represent a conformational state that facilitates substrate or
effector binding to SMYD3. The open state shows an enlarged opening to the substrate binding
site which may make it more accessible to a substrate than the closed state (Figure 1E). There is
over 35% increase in the accessible volume of the substrate binding cavity in the open state. The
first α helix of the CTD (αH) is responsible for the widening and increased accessibility. This helix
is involved in the direct lobe–lobe interaction and undergoes a large movement during the
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transition from the closed to open states (Figure 1D). Because of this movement, the substratebinding site is widened and more solvent-exposed in the open state.
The predicted Hsp90-binding site also becomes more solvent-exposed in the open state.
The C-terminal MEEVD motif of Hsp90 was predicted to bind between αJ and αL at the inner
surface of the CTD (Figure S2D) [94, 113]. This binding site is structurally similar to the putative
TPR peptide-binding site[94]. However, in the closed state the Hsp90-binding site is half-buried
due to the direct interaction between αH and the N-lobe. The binding site is further buried due to
the lobe-bridging β8–β9 hairpin sitting in front of the binding site. In the open state the distance
between the β8–β9 hairpin and Hsp90-binding site becomes significantly larger (Figure S2E) and
the volume of the binding site cavity is three times more than that in the closed state. Therefore,
the more exposed binding site in the open state may facilitate Hsp90 binding to SMYD3 and
provide a mechanistic basis for Hsp90-induced activity enhancement.
3.3 Distinct structural characteristics of the closed and open states
The closed and open states show distinct structural characteristics. They are different in
hydrogen bonding, salt-bridge, backbone angles and solvent accessible surface area. Hydrogen
bonding is different in pattern but not total number (Figure 2A). The closed state has an average
of 143.0 hydrogen bonds and open state 142.8. Their difference is not statistically significant (p =
0.498). However, there are 18 hydrogen bonds whose time- course pattern shows a significant
correlation with the conformational states (r > 0.5). Six of them are strongly correlated with the
open state and 12 with the closed state including the W300–S44 hydrogen bond. Residue D272 is
involved in two conformational state-specific hydrogen bonds. One hydrogen bond (S246–D272)
shows the strongest correlation with the closed state and the other (R249–D272) with the open
state. D272 is located at the junction between the post-SET and CTD (Figure S3A). In the open
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state, D272 moves slightly towards the substrate-binding site. The movement breaks its hydrogen
bond to S246 and leads to the formation of the hydrogen bond with R249. This indicates that the
hydrogen bonds S246–D272 and R249–D272 may be mutually exclusive. The time-course
patterns of these two hydrogen bonds show a strong negative correlation (r = −0.548).
The numbers of salt-bridges in the closed and open states are significantly different (p <
2.2 × 10−16). The closed state has 50.4 salt-bridges and open state 54.9. Nine salt-bridges show a
significant correlation with the closed state and 16 with the open state (r > 0.5) (Figure 2A). The
salt-bridge D332–K375 has the strongest correlation with the closed state (r = 0.907). This saltbridge stabilizes the closed state by pulling together the helices αJ and αL of the CTD (Figure
S3B). This also contributes to the buried state of the Hsp90-binding site. The salt-bridge D272–
R249 shows the strongest correlation with the open state (r = 0.838). This correlation is consistent
with the open-state-correlated hydrogen bonding between these two residues. The D272–R249
salt-bridge pulls αG towards the substrate-binding site and the pulling squeezes the bottom lobe–
lobe interface. The salt-bridge D209–K271 also shows a significant correlation to the open state (r
= 0.795). However, the direction of the force exerted by this salt-bridge is different from that by
the D272–R249 salt-bridge. The D272– R249 exerts the force along the axis of the rotation
describing the open-closed lobe–lobe motion. The D209–K271 exerts the force perpendicular to
this axis at the opposite surface of the substrate-binding site. The D209–K271 stabilizes the open
state by pulling the two lobes outwards.
Many residues show significant differences in the backbone torsion angles. Fifty-five
percent of residues are significantly different in Psi and 51% in Phi (p < 0.001). Twelve and seven
residues show more than 30° differences in Psi and Phi respectively (Table S1). There are 21
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Figure 10. Distinct structural characteristics
(A) Conformational state-correlated hydrogen bonds (top) and salt-bridges (bottom). Red and blue
lines indicate the presence of interactions and green lines absence. (B) Torsion angles of F362 as
a function of time. (C) Ramachandran plot of F362 trajectory.
residues whose Psi changes show a significant correlation with the conformational states and 12
residues for Phi (r > 0.5). Both Psi and Phi of residue F362 show strong correlation with the
conformational states (rpsi = 0.983, rphi = 0.839) (Figure 2B). There are clearly two populations
in its Ramachandran plot, one corresponding to the closed state and the other open state (Figure
2C). The neighboring residues of F362 also show large changes in the backbone angles and
significant correlation with the conformational states (residues 363– 366) (Table S1). These
residues are located in a short loop connecting the fourth and fifth helices of the CTD. The changes
in their backbone angles are correlated with a twisting motion between those two helices during
the conformational transition (see below). Their backbone-angle changes are also correlated with
a significant change in F362 interacting network. In the closed state, F362 forms a π-π stacking
interaction with Y358 (Figure S3C). In the open state, this interaction is replaced by the stacking
interaction with H366. As a result, F362 prevents M242 from interacting with H366. The loss of
this interaction may weaken the interaction between the N- and C-lobes near the axis of the rotation
describing the open-closed motion.
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The SASA of the closed and open states are significantly different (p < 2.2 × 10−16).
Unexpectedly, the closed state is more solvent exposed. The average SASA of the closed state is
116,339.3 Å2 and open state 116,250.9 Å2. Sixty-eight percent of residues show a significant
difference in SASA (p < 0.001). Fifty-six percent of these residues are more exposed in the closed
state than open state. There are 24 residues whose SASA changes show a significant correlation
with the conformational states (r > 0.5) (Figure S3D). Seventeen of them are located within the
CTD. These include three residues (M335, L344 and Q372) lining the Hsp90-binding site, which
are more exposed in the open state; and three residues (C309, A334 and C338) at the interface
between the second and third helices of the CTD, which become more buried in the open state.
The CTD is a key structural determinant of the closed and open states. The enrichment of residues
with the conformational state-specific SASA values reflects the characteristic structural changes
in the CTD defining the conformational states.
3.4 Different dynamical characteristics
The closed and open states have different dynamical characteristics. They are different in
flexibility, cross correlation, interatomic distance fluctuation and dynamical network. The closed
state is significantly less dynamical than open state (p < 2.2 × 10−16). The average atomic
displacement of the closed state is 0.81 Å and open state 1.24 Å (Figure S4A). The flexibility of
the CTD increases to a larger extent than the N-lobe in the open state. The average ratio of rootmean-square fluctuation (RMSF) of the open to closed states is 1.36 for the N-lobe and 1.83 for
CTD. However, the overall fluctuation pattern is not significantly different and the correlation
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Figure 11. Different dynamical characteristics
(A) Cross-correlation map of the trajectory. Left, the closed state; right, open state. Blue and red
indicate negative and positive correlation respectively. (B) Running cross correlation (RCC) of the
residue pairs W300–S44 and D272–D209. (C) Dynamical network analysis of the closed (left) and
open (right) states. Networks are colored according to communities. Points in the network are
nodes and lines between the nodes represent edges. Thicker lines depict the stronger edges or
stronger correlations.
between the two states is 0.753. Most of the residues in both states have a below 1 Å atomic
displacement. The least dynamical region is the SET domain in both states. The SET is the catalytic
domain responsible for cofactor and substrate binding. Several regions show a notable difference
in flexibility. In the closed state the regions around residues W300 and S44 are less dynamical than
those in the open state. The two regions interact with each other in the closed state and such
interaction appears to restrain their flexibility.
Dynamic cross-correlation patterns of the closed and open states are different. The closed
state shows a significantly lower level of correlated motions (p < 2.2 × 10−16). The average
correlation coefficients of the closed state and open state are 0.147 and 0.243 respectively. In both
states, the SET-I and the first three helices of the CTD show strong negative correlated dynamics
and the MYND motion is negatively correlated with the CTD motion (Figure 3A). Such negative
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correlated dynamics is consistent with the open-closed motion between the N- and C-lobes. The
open state shows many additional correlated motions. Among the most notable ones are those
between the last three helices of the CTD and many regions across all domains. To quantitatively
characterize the dynamical change in correlated motion, we developed the running cross
correlation (RCC) method (see Methods). RCC shows a time- course change in cross correlation.
It should smooth out short-term fluctuations and highlight longer-term trends or changes. RCC
analysis shows that the cross-correlation profile of the residue pair W300–S44 evolves and changes
during the simulation (Figure 3B). The motions of W300 and S44 are positively correlated in the
closed state when they interact, but change to a negative correlated dynamics after the
conformation is transited to the open state. Inter-residue RCC deviation analysis shows that W300–
S44 is among the residues pairs with the largest RCC variations (σ = 0.353) (Figure S4B). The
largest variation is found between the residue pair D272–D209 (σ = 0.384). These two residues
are not in the close proximity but both involved in conformational state-specific hydrogen bonding
and salt-bridges (Figure 2A).
The patterns of interatomic distance fluctuation are different between the closed and open
states. The closed state shows a significantly lower level of fluctuation (p < 2.2 × 10−16). The
average fluctuation of the closed state and open state are 0.598 Å and 0.880 Å respectively. Both
states show large distance variations between the lobes and the variations within the lobes are
significantly lower (Figure S4C). The average level of the between-lobe variations of the open
state is two times above that of the closed state. This indicates greater distance variability between
the N- and C-lobes in the open state. All components of the N- lobe in the open state show
significant distance variations with respect to the C-lobe, but only the MYND and SET-I shows
large variations in the closed state. The W300–S44 distance deviates about 0.519 Å and 2.075 Å
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in the closed and open states respectively. This difference is in agreement with the direct
interaction of the two residues in the closed state and the break of this interaction in the open state.
Dynamical network and communities are different between the closed and open states. There are
ten communities in the closed state and 11 in open state (Figure 3C). The community assignment
in both states is roughly correlated with the sequence- and structure- based domain assignment
[94]. However, there are significant differences in the ways of partitioning the domains into
communities. The most significant difference is found at the CTD. The CTD is split into three
major communities in the closed state, whereas in the open state it is split into two. In both states
the last three helices of the CTD form a separate community, but its first four helices form a single
community in the open state and are split in half along the middle of the helices in the closed state.
This indicates that the residues in the first four helices of the CTD have stronger
connections in the open state than they do in the closed state. Of note, the predicted Hsp90-binding
site is located between the two open- state-CTD communities. Another notable difference in the
dynamical networks is found at top of the substrate-binding site. Because of the direct lobe–lobe
interaction, there are inter- lobe edges at this location in the closed state; but without the equivalent
interaction, the open state has no edge. This indicates that the closed state may possess additional
paths for dynamical inter-lobe communication.
3.5 Substrates
The conformers in the closed and open states can be further clustered into substates. PC
analysis shows that both states consist of two major substates but the motions relating the substates
are different (Figure S5A). For the closed state, PC1 accounts for nearly one fifth of the overall
variance. The major motion along PC1 is a twisting motion of the N-lobe with respect to the Clobe (Figure S5B). The axis of the twisting passes through the MYND, β8– β9-containing β sheet
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and middle of the cofactor-binding site. For the open state, PC1 accounts for 38.4% of the overall
variance. The major motions along PC1 include a clamshell-like motion between the N-lobe and
first four helices of the CTD; and a twisting motion of the last three helices of the CTD with respect
to the N-lobe (Figure S5C). The axis of the former rotation aligns with the axis of the motion
depicting the conformational transition between the closed and open states (Figure 1B). In the
closed state, the PC1- described twisting motion affects the funnel-shape substrate-binding site.
The twisting pulls the β8–β9 hairpin and β12–αD loop together and apart. This alters the
dimensions of the substrate-binding site. The funnel-shape substrate-binding site has been
proposed to contribute to SMYD2 substrate recognition [113]. In the open state, the PC1-described
motions affect the dimensions of the inter-lobe gap and the distance between the CTD and β8–β9
hairpin (Figure S5C). As a result, both substrate-binding site and Hsp90-binding site are exposed
to different extents in the substrates.
3.6. Pathway of the conformational transition
Targeted molecular dynamics (TMD) simulation reveals the conformational transition
pathway between the closed and open states (Figure S5D). The forward and reverse transitions
follow similar structural conversion processes. The two conformational states are interconverted
by a reversible CTD rotation. The axis of the rotation passes through the fifth helix (αL) of the
CTD parallel to the helical axis. αL is relatively static during the conformational transition. The
average RMSF of this helix is 1.7 Å compared to 4.2 Å for the first four helices of the CTD and
2.2 Å for the last two helices. The differences in these RMSFs are significant (p < 9.0 × 10−6). αL
is involved in direct interaction with the β8–β9 hairpin (Figure S5C). This interaction secures αL
in position, appears to assist in rotating the CTD around this axis and thereby may contribute to a
proper conformational transition between the closed and open states. In agreement with the
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conventional molecular dynamics (Figure 1E and S2D), TMD also shows that the conformational
transition regulates the degrees of exposure of the substrate-binding site and Hsp90-binding site.
3.7. Small angle X-ray scattering
To provide experimental support for the MD-sampled open state, the solution structure of
SMYD3 was characterized using small angel X-ray scattering (SAXS) (Figure 4A). SAXS analysis
shows that the radius of gyration (Rg) of SMYD3 is 24.5 Å in solution and Dmax (maximum
particle dimension) 78.0 Å. These values are similar to the Rg (23.2 Å) and Dmax (77.8 Å)
calculated from the crystal structure. The ab initio shape modeling shows that the dummy atom
model visually matches the crystal structure (Figure 4B). The last three helices of the CTD fits
into a slightly protruding envelope and there is a miniature groove between the N- and C-lobecorresponded regions. However, this dummy model can also be fitted equally well with an open
state structure (Figure 4B). This indicates that the low resolution of SAXS model is unable to
distinguish between the closed and open states.
The theoretical scattering curve calculated from the crystal structure does not completely
fit with the experimental data. The fitted χ2 is about 2.68. At the low q regions, the fitted curve is
in a good agreement with the experimental data, but the high-q regions beyond 0.15 Å−1 are not
being well explained by the fitting (Figure 4A). This suggests that the crystal structure is somewhat
different from the solution structure; more strictly, it is different from the average structure of the
SMYD3 conformational space. However, the fitting statistics can be improved by normal mode
analysis (NMA). NMA probes the large-scale motions in SMYD3 and estimates the structural
flexibility to improve agreement with the SAXS data. The best model from the NMA has an
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Figure 12. Small-angle X-ray scattering
(A) Experimental scattering curve (red) overlaid with theoretical scattering curves calculated from
a closed (green) and open (blue) SMYD3 structure. The q range used for model fitting is indicated
by arrows. (B) Ab initio dummy atom model (red) superimposed with a closed (green) and open
(blue) structure. (C) An open structure derived from normal mode analysis.
improved χ2 of 1.72. The CTD in this model undergoes large conformational changes including a
twisting motion of the first two helices and an outward-bending motion of its second half (Figure
4C). The lobe–lobe bridging interactions at the W300–S44 interface in this model break. Such a
conformation resembles the open state structures sampled in the above MD analysis.
To correlate the MD simulation with the SAXS experiment, the entire MD trajectory was
fitted to the experimental data. The average χ2 of the trajectory is 3.37 (Figure S6A). The closed
state shows significantly lower χ2 than the open state (p < 2.2 × 10−16). The average χ2 of the
closed state is 2.71 and open state 3.90. This would indicate that the closed state fits better to the
SAXS data than the open state. However, the best fitting conformer adopts an open structure. 32%
of the open state has a χ2 less than the average value of the closed state. This is consistent with
normal mode analysis where the open CTD structures show the best agreement with the
experimental data (Figure 4C). This also indicates that the combination of all motions in a
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conformational state determines the results of the experimental data fitting, rather than the open–
closed motion alone (Figure 1D and S5). In the open state, the χ2 is widely spread with a σ value
of 1.63 compared to 0.22 for the closed state (Figure S6A). This is consistent with highly
dynamical nature of the open state (Figure S4A). The Rg of the trajectory shows a mixed
negative/positive correlation with the χ2 (Figure S6B). The open state has larger Rg values than
the close state (p < 2.2 × 10−16). The average Rg for the closed state and open state are 23.2 Å
and 23.6 Å respectively. This indicates that the closed-state structures are more compact than the
open-state structures. The Rg is strongly negative correlated with the χ2 when it is less than 23.4
Å (r = 0.612) and changes to a positive correlation at the higher values (r = 0.874) (Figure S6B).
The negative correlated region samples both closed and open conformers and the population of the
closed state in this region is 2.5 times more than that of the open state. However, 75% of the top
1% best fitted conformers adopt an open conformation. This further indicates that some of the
open state structures are closer to the average structure of the SMYD3 conformational space.
Conclusion
SMYD proteins are an exciting field of study as they are linked to many types of cancerrelated pathways [4]. Cardiac and skeletal muscle development and function also depend on
SMYD proteins opening a possible avenue for cardiac-related treatment [94]. Among SMYD
proteins, SMYD3 has received the most attention because of its involvement in epigenetic and
non-epigenetic regulation of numerous cancerous genes [4, 5, 94, 95]. Due to its tumor-growthinducing role and association with poor prognosis SMYD3 has emerged as a key target for anticancer therapies [114]. However, the biochemical mechanism of SMYD3-mediated methylation
remains elusive. The “closed” substrate-binding site and poor in vitro H3K4 methyltransferase
activity have led to arguments that SMYD3 is not a histone lysine methyltransferase and the in
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vivo-associated H3K4 tri-methylation might be catalyzed by other methyltransferases [5, 68]. Such
arguments have obscured our understanding of the role of SMYD3 in epigenetic gene regulation,
where a completely different interpretation of SMYD3 function could result from the arguments:
SMYD3 functions as a histone code “writer” defining chromatin states, or only serves to anchor
other chromatin-associated proteins through its sequence-specific DNA binding. Here we provide
theoretical and experimental evidence that SMYD3 can adopt an open conformation. This new
open conformational state is substantially different from the crystal structure-like closed state. The
two states are related by a striking clamshell-like motion of the C-lobe with respect to the N- lobe
and SMYD3 is transited by this large motion from a ligand binding-incapable state to a bindingcapable state. A recent MD study revealed that the CTD can undergo a similar hinge-like motion
resulting in expanded substrate binding crevice [115]. In the absence of the cofactor, the CTD
samples more open configurations than it does in the presence of the cofactor [115]. It was
postulated that the cofactor acts like a key and locks SMYD3 in a closed conformation [115].
However, the present MD study shows that SMYD3 can undergo a spontaneous conformational
transition from the closed to open states in the presence of the cofactor. The conformational
transition leads to the enlarged opening to the substrate binding site in the open state which could
increase histone tail accessibility to the active site cavity and target lysine access channel. This
would then provide the mechanism for SMYD3 activity on both H3K4 methylation and H3K4me3
binding. A recent study showed that SMYD3 interacts with H3K4me3 modified histone tails,
which facilitates its recruitment to the core promoter regions of most active genes [95].
The conformational transition pathway involves a reversible twisting motion of the CTD
and the transition from the closed to open states breaks the top lobe–lobe interface resulting in a
more accessible substrate-binding site and Hsp90-binding site. Many structural and dynamical
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changes are associated with this conformational transition and these changes may either contribute
to the transitional process or stabilize the particular conformational states. While the exact portion
of each conformational state in solution is unknown, the closed state statistically better fits the
experimental data than the open state, but the best fitting conformers adopt an open structure.
Nevertheless, the presence of both closed and open states in the conformational ensemble suggests
two possible, mutually non-exclusive models for SMYD3 functional regulation. First, a
conformational selection mechanism may regulate SMYD3’s ligand binding. In the
conformational selection model, the intrinsic dynamics of the protein lead it to spontaneously
transition between a stable unbound and a less stable bound conformation. The apo-protein visits
the bound state with significant probability and the ligand can bind directly to this conformation
shifting the distribution of conformers towards the bound population [116]. Therefore, the open
state with the exposed ligand- binding sites suggests that the ligand binding of SMYD3 may be
regulated by the conformational selection mechanism. In addition, the highly correlated inter-lobe
dynamics in the open state may facilitate SMYD3 promiscuity through the conformational
selection mechanism, allowing the structural adaptation to different substrates. The conformational
selection mechanism has been shown to be involved in promiscuous ligand binding and this
assumes that the protein needs to visit multiple binding conformers capable of binding different
ligands [116]. In SMYD3, the inter-lobe dynamics will alter the size of the substrate- binding site.
The coupling of the two lobes by the correlated motion might thus offer the specificity and
promiscuity for substrate recognition.
Second, our results provide a model for possible allosteric regulation and a population shift
between the two conformational states may underlie the functional control of SMYD3. Recent data
suggest that allostery can be mediated by transmitted changes in protein dynamics [117]. The
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binding of an allosteric effector can result in the redistribution of protein conformational ensembles
and cause changes in catalytic or ligand binding competence [117]. DNA binding to the N-lobe
has been shown to enhance SMYD3 methyltransferase activity [64]. The interaction of SMYD3
with BRD4 mediates the recruitment of transcriptional cofactors at the myostatin gene and
regulates skeletal muscle atrophy [12]. SMYD3 interacts with PC4 in tumor cells and such
interaction stimulates oncogenic gene expression through deposition of H3K4 tri-methylation [97].
All these interactions are mediated via the MYND domain of SMYD3, but the structural and
dynamical consequences of the interaction remain unknown. One possibility is that the interaction
may affect the domain dynamics and inter- lobe dynamical correlation. Such an effect could be
transduced to other parts of the protein through the edges bridging the dynamical communities and
this might in turn cause a population shift between the existing conformational states, thereby
modulating active site or binding site geometries. In summary, a detailed study of SMYD3
structure and dynamics is of functional and therapeutic importance. The identification of the open
conformational state provides the basis for the conformational selection mechanism and allosteric
regulation.
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CHAPTER 3 MOLECULAR DYNAMICS SIMULATION REVEALS CORRELATED
INTER-LOBE MOTION IN PROTEIN LYSINE METHYLTRANSFERASE SMYD2
*Published in PLoS One. 2015 Dec 30;10(12):e0145758. doi: 10.1371/journal.pone.0145758.
All authors agreed with including their work in this dissertation.
Introduction
SMYD is a special class of protein lysine methyltransferases involved in heart and muscle
development[1, 94]. SMYD linked to tumorigenesis opens a possible avenue for cancer treatment
[4, 94]. SMYD proteins contain five members, SMYD1–5 [24, 35, 39, 57, 94]. Each member
contains a conserved SET domain that is “split” by a zinc-finger MYND domain [94]. The SET
domain is a catalytic unit responsible for protein lysine methylation [36]. The MYND domain is a
protein–protein interaction module and has also been shown to have a DNA binding ability in
SMYD proteins[4, 37, 38]. Among SMYD proteins, SMYD2 has the broadest substrate specificity.
In addition to histone proteins, SMYD2 is able to methylate p53, retinoblastoma tumor suppressor
(RB), estrogen receptor α (ERα), poly(ADP-ribose) polymerase 1 (PARP1), and heat shock
protein-90 (Hsp90)[3, 49, 50, 94]. Through these methylations, SMYD2 is involved in several
cellular processes including cell cycle progression, apoptosis, cellular differentiation, DNA
damage response, and epigenetic gene regulation [94].
The crystal structures revealed that SMYD proteins have a bilobal structure[24, 35, 39, 57,
94]. The N- lobe contains the SET, MYND, SET-I, and post-SET domains, and the C-lobe is made
up of the CTD domain. The cofactor-binding site is located in a surface pocket in the N-lobe. The
substrate-binding site is located between the N-lobe and CTD and situates at the bottom of a deep
cleft. The orientation of the CTD is different among the SMYD family. This difference is reflected
by the relative positions of the N- and C-lobes resulting in open and closed structures [39]. In
SMYD2 the CTD is flexible and can undergo a conformational change upon binding to different
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cofactors [24]. Such a conformational change results in two SMYD2 structures with a slight
difference in the size and shape of the substrate-binding pocket. The functional significance of the
SMYD2 conformational change is still unknown. One possible consequence is that the
conformational change may affect substrate access to the active site, thereby regulate substrate
binding [57]. Another possibility is that the conformational change may be important for SMYD2
promiscuity allowing the structural adaptation to different substrates [57]. Finally, the
conformational change may provide an allosteric mechanism for the effector-induced activity
enhancement and change in substrate specificity [24].
Current understanding of the SMYD conformational change is limited to the structural
differences observed in the crystal structures. The dynamical nature of the SMYD proteins is still
poorly understood. It remains unknown of the structure of dynamical networks and the pattern of
correlated domain motions, both of which are fundamental in mediating substrate recognition and
allostery [118, 119]. Using the molecular dynamics (MD) simulation, this study reveals that
SMYD2 exhibits a negative correlated inter-lobe dynamics. Dynamical network analysis suggests
optimal and suboptimal paths for such a correlation. This study provides insight into SMYD2
dynamics and could prove valuable in understanding SMYD2 substrate specificity.
Materials and Methods
Molecular Dynamics Simulation
Molecular dynamics simulation was performed using NAMD [103]. CHARMM force field
was used to parameterize the simulation. Initial structure for simulation is the crystal structure of
the SMYD2–SAH complex (PDB code: 3QWV; SAH: S-adenosyl-L-homocysteine or AdoHcy).
The missing residues of the structure including two N-terminal residues and one C-terminal residue
were filled using SWISS-MODEL [120]. The system was solvated inside an orthorhombic box of
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water molecules with a 13 Å padding in each direction. The system was then neutralized with NaCl
at a concentration of 0.15 M. The final system contained 78,008 atoms. Simulation was performed
with a 1 fs time step. Particle Mesh Ewald was used to treat long- range electrostatic interactions
and a cutoff of 12 Å was used for non-bonded interactions. Periodic Boundary Conditions were
applied during the simulation. The simulation started with 2,000 steps of energy minimization.
The first half of the minimization had harmonic restraints on the protein, and the second half
unrestrained minimization. The minimized structure was then slow heated from 0 to 300 K over
300 ps. At each integration step velocities were reassigned and the temperature was incremented
by 0.001 K. The heated structure was then equilibrated for 300 ps and velocities were rescaled to
300 K at every integration step. The production run was performed in the NVE (microcanonical)
ensemble at 300 K. The total simulation time was 2 ns and coordinates were recorded every 1 ps.
Principal Component Analysis ad Clustering
Principal component (PC) analysis was performed using Bio3D [104]. The entire 2 ns
trajectory of 2000 frames was used in the analysis. The overall translational and rotational motions
in the trajectory were eliminated by least squares fitting to the first frame. A 3 N × 3 N covariance
matrix were generated using Cartesian coordinates of Cα atoms. Diagonalization of the covariance
matrix generated 3 N eigenvectors, each having a corresponding eigenvalue. The trajectory was
projected onto a particular eigenvector to reveal concerted motions. Clustering of the trajectory in
the PC space was performed using k-means and hierarchical clustering algorithms. k-means
partitions the observations into k clusters by minimizing the mean squared distance from each
observation to its nearest cluster center. Hierarchical clustering builds a hierarchy of clusters based
on the distance between the observations.
Dynamical Network Analysis
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Dynamical network analysis was done in VMD according to previous protocols [107, 108].
Each amino acid in the network was represented by one node and SAH by three nodes. Amino
acid nodes were centered on Cα atoms and SAH nodes were located at atoms Cα, C4’, and N9.
The edges between nodes were drawn if the residues were within a cutoff distance of 4.5 Å for at
least 75% of the trajectory. The edge distances were derived from pairwise correlations which
define the probability of information transfer across the edge. Correlations were calculated from
the trajectory by the program Carma [105]. The community substructure of the network was
obtained using the Girvan-Newman algorithm. Nodes in a community have more and stronger
connections within that community than the nodes in other communities. Critical nodes were
defined based on the betweenness, which measures the importance of a node to the entire network.
Critical nodes connect communities and lie at the interface between pairs of communities. Optimal
and suboptimal paths were generated from the initial dynamical net- work matrix. The optimal
path is the shortest path between two given nodes. Suboptimal paths are paths that are slightly
longer than the optimal path.
Results
1. Dynamical Details of SMYD2-SAH Complex Structure
The simulation was performed using NAMD [103]. The starting structure is the crystal
structure of SMYD2–SAH complex. The simulation was done in the NVE ensemble. The system
was slow heated and equilibrated before 2 ns production simulation. The stability of the system
during the production stage was evident by stable kinetic energy, potential energy, temperature,
and RMSD (root mean square deviation) (data in S1 Fig and Fig 1A). The protein structure does
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Figure 13. SMYD2 dynamics
(A) Backbone RMSD during the simulation. RMSD was calculated relative to the crystal structure.
(B) Root mean square fluctuation (RMSF) of Cα atoms during the simulation (black line). Red
line depicts the RMSF values converted from crystallographic B-factors. The inset depicts the
distribution of the simulation RMSF. (C) Ribbon diagram of SMYD2 structure at 2 ns. The
structure is colored according to the simulation RMSF. Color scale from blue to red depicts low to
high atomic fluctuations. Secondary structures, α-helices and β-strands are labeled and numbered
according to their position in the sequence. SAH is represented by sticks and zinc ions by purple
spheres. (D) Cross-correlation map of the trajectory. Blue indicates a negative correlation between
residue fluctuations, and red depicts a positive correlation. Lobe and domain structures of SMYD2
are indicated on the top of the map. (E) Visualization of residue–residue cross-correlations.
SMYD2 is depicted by green coils. Blue and red lines indicate negative and positive correlated
motions. (F) Inter-residue distance deviation map. Color scale from blue to magenta depicts small
to large distance deviations. (G) Distance fluctuation of Y311–G46 during the simulation. Color
bars depict the conformer clustering results obtained in Fig 2.
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not significantly deviate from the crystal structure. The backbone RMSD fluctuates between 1.4
Å and 2.5 Å with an average value of 2.0 Å.
SMYD2 dynamics revealed by the MD is similar to that from the crystallographic B factorbased analysis (Fig 1B and 1C). Most of the residues have a below 1 Å atomic displacement. The
least dynamical region is the SET domain. The SET is the catalytic domain responsible for cofactor
binding and substrate binding. The post-SET which is tethered to the SET by a zinc ion also shows
a less dynamical structure. The most dynamical region in SMYD2 is found in the N-termini. In the
crystal structure the first two N-terminal residues were not observed. The second largest
displacement is found at the linker region between the post-SET and CTD. This non-conserved
region has a variable length in SMYD proteins. This region has been proposed to act as a hinge
for inter-domain movement [24, 39]. Large motion is also observed for parts of the MYND and
CTD. In CTD, the most dynamical regions are the linker regions between the pairs of up-down
helices. In MYND, the variable regions are the N- and C-terminus of the kinked helix αA and a
loop between β5 and β6. In SET-I, the most dynamical regions are the end of the first helix (αB)
and the beginning and end of the second helix (αC), and the loop forming the cofactor-binding site
is relatively static.
2. Correlated Inner-Lobe Motion
The CTD and N-lobe show strong negative correlated dynamics (Fig 1D). The regions in
the CTD involved in such a correlation include residues 300–315, 337–360, and 390–400. These
regions are among the most dynamical regions in the structure (Fig 1B) and located at the inner
surface of the C-lobe (Fig 1E). The correlated regions in the N-lobe are divided into seven zones
spanning from residues 40–200. The zones include the following regions: (I) residues 41–53; (II)
68–73; (III) 85–95; (IV) 100–115; (V) 150–160; (VI) 183–185; (VII) 195–200. These zones spread
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across the MYND, SET-I and part of the SET domain but are clustered at the inner face of the Nlobe. As a result, the two correlated sets of residues are facing each other across the gap of the Nand C-lobes (Fig 1E). The residues in each set show positive correlated intra-lobe dynamics,
whereas the two sets are related by the negative correlated inter- lobe dynamics (Fig 1D and 1E).
During the simulation the contact distances between the residue-pairs of the two sets vary
significantly (Fig 1F). The level of variation is two times above the average variation. This
indicates a relatively large distance variability between the N- and C-lobes. This together with the
negative correlated inter-lobe dynamics suggests a possible clamshell-like motion or open–closed
motion between the lobes. The distances of the two representative residues, Y311 in the C-lobe
and G46 in the N-lobe, range from 8.7 to 16.0 Å during the simulation. The fluctuated pattern of
the distance indicates a slightly open and closed con- formation (Fig 1G).
3. Principal Component Analysis
To further understand SMYD2 correlated dynamics, principal component (PC) analysis
was performed using Cα position covariance (Fig 2A). The first PC accounts for more than one
fourth of the overall variance. The second PC accounts for 10%. The first three components
together account for 45%. The individual component contributions afterward drop below 6%. The
first PC describes a twisting motion of the CTD with respect to the N-lobe and a spring- bending
motion within the MYND (Fig 2B). The second PC is dominated by a clamshell-like motion
between the N- and C-lobes. It is therefore that the variance in the PC1–PC2 plane essentially
dictates the negative correlated inter-lobe dynamics. Based on these variances, the conformers
throughout the simulation were grouped into four clusters using k-means algorithm (Fig 2C). The
number of clusters was chosen based on the “elbow criteria”. At a cluster count of four the
BSS/TSS (Between-group Sum of Squares/Total Sum of Squares) ratio is 82.8%. Similar
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Figure 14. Principle component analysis
(A) Scree plot showing the proportion of variance against its eigenvalue rank. (B) Visualization of
the motions along PC1 (left) and PC2 (right). The most dissimilar structures along a given PC are
depicted by thicker coils. The interpolated structures produced by Bio3D [104] are shown by
thinner coils. Color scale from blue, green, to red depicts low to high atomic displacements. (C)
Projection of the trajectory onto the planes formed by the first three principle components.
Conformers are colored according to the k-means clustering: cluster 1, black; 2, red; 3, blue; 4,
green.
clustering was obtained using hierarchical clustering algorithm (data in S2 Fig). Cluster 1
populates in the first 0.25 ns and between 0.7 and 0.9 ns. Cluster 2 is intertwined with Cluster 1
(0.25–0.7 ns and 0.9–1.0 ns). Cluster 3 is sampled in a time window of 1.0–1.5 ns. Cluster 4 lasts
for the remainder of the simulation. This PC1–PC2 plane-based clustering appears to correlate
with the pattern of distance fluctuation between Y311 and G46 (Fig 1G). The Y311–G46 distance
represents the distance between the N- and C-lobes or the open/closed state of the structure. Cluster
1 and 4 correspond to the closed state, while cluster 2 and 3 sample the open one.
4. Dynamical Network Analysis
Dynamical network analysis was performed to define the allosteric paths for SMYD2
correlated inter-lobe dynamics. This analysis revealed nine communities in the dynamical
structural net- work (Fig 3A). The community assignment is roughly correlated with the sequence-
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Figure 15. Dynamical network analysis
(A) SMYD2 dynamical network. The network is colored according to communities. Points in the
network are nodes, and lines between the nodes represent edges. The thicker lines depict the
stronger edges or stronger correlations. Critical nodes are colored in purple. (B) Optimal and
suboptimal paths between Y311 and G46. The optimal path is colored in red and suboptimal paths
in blue. The edge thickness is weighted by the number of suboptimal paths crossing the edge.
Residues along the optimal path are labeled.
and structure-based domain assignment [35, 39]. The SET is split into two communities largely
corresponding to the S-sequence and core SET. The cofactor product SAH is associated with the
S-sequence community. This indicates a stronger correlated motion between SAH and the Nterminal S-sequence. The S-sequence has been shown to be involved in cofactor binding [24, 35,
39]. Mutation of two Gly residues in this sequence abolished SMYD1 enzymatic activity [35]. The
SET-I, which is also involved in cofactor binding, forms a separate community. The MYND, a
protein–protein interaction module, forms another community. There is a separate community
formed at the interface of SET, MYND, and SET-I. This community contributes the residue
Phe184 to the target lysine access channel. However, other two aromatic residues (Y240 and
Y258) in this channel belong to the S-sequence-containing community. Most of residues in the
post-SET belong to one community. This community also contains the residue H207 from the
conserved active site motif NHS. H207 chelates the zinc atom of the post-SET, which may result
in such an association. Other two residues (N206 and S208) in the NHS motif belong to the Ssequence-containing community. In CTD there are three communities formed by the first helix
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(αH), αI–αJ–αK, and αL–αM–αN. The predicted Hsp90 binding site is located between the second
and third communities, which is also the extended ribosomal binding site[24, 57, 94].
The communication between network communities is mediated through critical nodes
[108]. Such nodes are important for allosteric signal transduction and dynamical correlation
between the communities[108, 121]. Of note, the β8–β9 hairpin contains four critical nodes
(residues 190–193). These nodes form a bridge connecting the N- and C-lobes (Fig 3A). Two of
these nodes (residues 190 and 191) have direct interaction with the CTD. Disrupting this
interaction has been found to reduce SMYD2 methyltransferase activity [58]. This suggests that
the β8–β9 hairpin may represent an optimal path for dynamical inter-lobe communication. The
optimal and suboptimal paths were generated between Y311 and G46. As mentioned earlier, these
pair of residues move in concert toward the opposite direction. Their dynamical relationship can
represent the open and closed state of the structure and correlated inter-lobe dynamics. The optimal
path between the two residues passes through the β8–β9 hairpin (Fig 3B). All suboptimal paths
also pass through the hairpin. The β8–β9 hairpin occurring in the highest number of suboptimal
pathways may thus be necessary to guarantee an effective pathway for inter-lobe communication.
Discussion
The

crystal

structures

revealed

that

SMYD

proteins

adopt

different

CTD

conformations[24, 35, 39, 57, 94]. SMYD1 has an open CTD structure with the substrate-binding
cleft completely exposed. SMYD3 has the narrowest substrate-binding cleft due to the direct
CTD–N-lobe interaction [39]. SMYD2 is like a conformational intermediate, and when different
cofactors bound, the CTD exhibits different conformations [24]. These data have suggested the
dynamical nature of the CTD and a possible open–closed motion of the two lobes [94]. Our MD
simulation of SMYD2 structure supports an open–closed motion. The simulation reveals that
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SMYD2 exhibits a negative correlated inter-lobe dynamics, and this correlated dynamics is
described by a twisting motion of the CTD with respect to the N-lobe and a clamshell-like motion
between the lobes. Correlated inter-domain motions may mediate fundamental protein functions
such as substrate recognition [119]. In SMYD2 the substrates bind to the protein in a U-shaped
conformation[57, 58]. Both the N- and C-lobe contribute to the binding. The inter-lobe dynamics
will alter the size of the substrate-binding site. The coupling of the two lobes by the correlated
motion might offer the specificity and promiscuity for substrate recognition. Correlated interdomain motions are also important for allostery [118]. In SMYD2 the cofactors exhibit allosteric
effects. Binding of sinefungin and SAH to the cofactor-binding site in the N-lobe caused a
structural difference in the CTD [24]. Such a long-range structural effect could not be explained
by the crystallographic studies [24], but the correlated inter-lobe dynamics might provide a signal
transduction pathway enabling a long-range domain–domain communication.
A complex mechanism regulates SMYD biochemical function. Binding of Hsp90 to the
CTD significantly enhances the activity of SMYD proteins[4, 41, 42]. For SMYD2, Hsp90 binding
not only increases the activity but also changes the substrate specificity [41]. Both SMYD2 and
SMYD3 interact with DNA[4, 63]. DNA binding to the MYND has been shown to enhance
SMYD3 enzymatic activity [64]. The mechanism of such an activity enhancement is unknown,
but one possible mechanism is that the binding may affect the domain dynamics and inter-lobe
dynamical correlation. Such an effect could be transduced to other parts of the protein through the
critical nodes bridging the communities, which in turn might impact substrate binding and cofactor
binding.
Studying SMYD2 conformational dynamics is of therapeutic interest. Dynamical
information of SMYD2 structure would facilitate receptor-flexibility-enabled drug design. The
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conformational states sampled by the MD simulation can be used in ensemble docking. In addition,
the identification of the critical nodes and optimal path mediating the dynamical network
communication could offer new strategies to manipulate SMYD2 function. Disrupting a specific
network communication could represent a rational approach for the design of drugs with improved
potency and selectivity. In summary, the MD simulation of SMYD2 structure has revealed that
SMYD2 exhibits a negative correlated inter-lobe dynamics and provided additional insight into
the structure of this multifunctional protein lysine methyltransferase.
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PART II. ALTERNATIVE STRATEGIES TO INHIBIT POST-TRANSLATIONAL
MODIFICATIONS
CHAPTER 4 CRYSTAL STRUCTURE OF SMYD2 – PARP1 COMPLEX, A NOVEL
BINDING SITE IDENTIFIED.
Introduction
Poly (ADP-ribose) polymerase 1 (PARP1) is a mammalian, multifunctional enzyme
involved in DNA repair, genome stabilization and chromatin restructuring [122-125]. Upon DNA
damage, PARP1 serves as a first responder to recognize single and double stranded breaks (SSB
and DSB), and recruits proteins necessary for repair and signaling the DNA damage response
(DDR) pathway. Protein recruitment towards damaged DNA sites is made possible by the ADPribosyl transferase activity of PARP1, which serves to transfer linear or branched moieties of ADPribose upon itself and target nuclear proteins [126-129]. PARP’s basal enzymatic activity is low,
but activity can be enhanced through DNA binding, protein binding partners and post-translational
modifications [127, 130-133]. Recently, a study found PARP1 is methylated at K528 by SMYD2,
and methylation of K528 stimulated ADP-ribosyl activity and the DNA damage response [52].
SMYD2 (SET and MYND domain-containing protein 2) is a protein lysine
methyltransferase reported to be involved in cardiomyocyte function, macrophage activation and
cancer progression [14, 16-18, 51, 134]. The molecular mechanism of SMYD2 in relation to these
responses have been fairly documented. One of the earliest studies found SMYD2 to methylate
p53 at lysine 370 impairing p53’s function to promote p21 and MDM2 expression [3]; however,
SMYD2’s anti-apoptotic role is not solely dependent on methylating p53 [16, 19]. Indeed, later
studies found SMYD2 to methylate a library of protein substrates including Hsp90, estrogen
receptor α (ERα), retinoblastoma (RB1), MAPKAPK3, all of which yield unique functional ends
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[2, 19, 50, 52, 71]. Understanding how SMYD2 recognizes these reported substrates at the
molecular level remains a challenge.
In order elucidate the mechanism of SMYD2 methylation and regulation, several efforts
were made to understand the structure and biochemistry of SMYD2. Biochemical studies reported
weak methyltransferase activity [61]. A possible explanation for low activity could be explained
by the accessibility of the substrate channel. Crystal structures of SMYD2 demonstrate the TPRlike domain (C-lobe) appears to shade over the substrate channel and limit the space for peptide or
protein entry . At the moment, two SMYD2-peptides (p53 and ERa) structures have been reported.
Both peptides offer similar yet unique structures within the substrate channel offering insight into
the multiple configurations a substrate can be recognized by SMYD2 [54, 57, 58].
In this study, we solved the crystal structure of SMYD2 in complex with PARP1 peptide.
Unexpectedly, we were able to map only four amino acids in the primary site, including the target
lysine and P-1 leucine. Since most of the residues in the peptide were unstructured, this may
provide supporting evidence that the target lysine and P-1 leucine are necessarily and significant
for SMYD2 substrate recognition and methylation [135]. However, we identified a second peptide
bound in a separate site that appears to wedge between the N- and C-lobe of SMYD2. The function
of this unexplored site may have implications in trafficking SMYD2 substrates into the substrate
channel.
Materials and Methods
Protein Expression and Purification
The open reading frame of human SMYD2 was cloned into pCDF-SUMO vector and
transformed into BL21 (DE3) cells for recombinant protein expression. Cells grew to an optical
density of 0.4 – 0.6 and protein expression was induced with 0.1 mM IPTG. Growth continued
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overnight at 15°C. Harvested cells were suspended in binding buffer (20 mM sodium phosphate,
500 mM NaCl, 5% glycerol, 20 mM imidazole, 5 mM BME) and lysed using a French Press, and
the supernatant was collected for purification. His6-SUMO-SMYD2 was captured on a HisTrap
column (GE Healthcare) and eluted out by applying an elution buffer (20 mM sodium phosphate,
500 mM NaCl, 5% glycerol, 500 mM imidazole, 5 mM BME) gradient. Fractions containing His6SUMO-SMYD2 were pooled and dialyzed in binding buffer. Ulp1 was added to cleave off the
His6-SUMO tag. The native SMYD2 protein was collected by passing the protein pool through the
HisTrap column. Finally, SMYD2 was further purified through a Superdex 200 column (GE
Healthcare) into gel filtration buffer (20 mM Tris pH 7.5, 150 mM NaCl, 5% glycerol, 5 mM
BME). Fractions containing pure SMYD2 were pooled, concentrated to 20 mg/mL and stored in
the -80°C.
Crystallization, Data Collection and Structure Determination
All crystals were prepared using the hanging drop method at 20°C. Crystal seeds were
prepared by incubating 10 mg/mL SMYD2, 1 mM PARP1 peptide (RMKLTLKGGAAVD), and
600 µM SAH in buffer (20 mM HEPES 7.5, 50 mM NaCl) for 2 hours at 4°C and crystallized in
a 1:1 volume of protein and crystallization solution (20% PEG 3350, 0.1 M Tris pH 7.5 and 5%
ethanol). Seeds were crushed and crystallized again by supplementing 1.5 mg/mL SMYD2 and 1
mM PARP1 peptide into the crystallizing drop. Crystals typically achieved full size after one week.
SMYD2-PARP1 crystals were harvested and flash-frozen in liquid nitrogen. X-ray diffraction data
was collected at Advance Photon Source (beamline 21-ID-G) and images were processed using
XDS and AIMLESS [136, 137]. Crystals were indexed to C121 space group containing 2
molecules per asymmetric unit. Phases were obtained through molecular replacement using human
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SMYD2 structure (PDB ID: 5KJK) as a search model. Several rounds of model building and
refinement were carried out in Coot and PHASER, respectively [138, 139].
Isothermal Titration Calorimetry
ITC titrations were carried out on a NanoITC SV calorimeter (TA Instruments) at 27°C
whilst stirring at 375 rpm. All experiments were performed with 16 (15 µL) injections spaced 200
seconds apart. The first (3 µL) injection was excluded from modeling. Protein samples were
dialyzed in the same buffer (25 mM Tris pH 7.5, 50 mM NaCl) and PARP1 and p53 peptides were
dissolved in the buffer dialysate. The sample cell was loaded with approximately 1.2 mL of 40 µM
SMYD2 solution, and the injection syringe was loaded with approximately 250 µL of 631 µM
PARP1 peptide (RMKLTLKGGAAVD) solution. Protein and peptide concentrations were
quantified using a Direct Detect (Millipore Sigma). Data was processed and fitted in NanoAnalyze
(TA Instruments).
Results
Overall structure of the SMYD2-PARP1 complex
The SMYD2 structure in complex with PARP1 and s-adenosylhomocysteine (SAH) was
solved at 2.1Å using molecular replacement. The overall fold of SMYD2 possesses a bilobal
structure with a deep crevice separating the two lobes. The N-lobe (residues 5 – 278) is divided
into four domains: SET, MYND, SET-I and post-SET. The SET, SET-I and post-SET domains
associate to form an evolutionary conserved fold that make up the core SET domain structure. The
MYND domain possesses a zinc-finger fold that sits outside of the SET domain. This domain
doesn’t contribute to substrate or cofactor binding but has been reported to contribute binding
towards EBP41L3 through a PXLXP motif [41]. The cofactor, SAH sits inside a deep pocket
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Figure 16 Overall structure of SMYD2-PARP1 complex
(A) Ribbon and (B) surface representation of SMYD2-PARP1 complex. The S-sequence, MYND,
SET-I, core SET, post-SET, and CTD are colored in lime green, blue, pink, green, cyan, and red,
respectively. Secondary structures are labeled based on their position in the sequence. PARP1
peptides inside substrate and secondary binding site are colored in magenta and sky blue,
respectively.
formed the by SET (β1-β2) , SET-I (310-1–310-2) and post-SET domains (αE-αF) and essentially
binds as previously described from another report [57]. The C-lobe or C-terminal domain (CTD)
(residues 279-433) folds similarly to tetratricopeptide repeat (TPR) domains [35, 140]. The
purpose of the CTD in SMYD proteins is unknown, but reports suggest the CTD contribute
towards substrate and Hsp90 binding [54, 57, 58, 102]. Previous reports observed a significant
increase in histone methylation from SMYD1, SMYD2 and SMYD3 in the presence of Hsp90;
therefore, the CTD may play a role in modulating SMYD methylation [4, 41, 42]. Two binding
sites of the PARP1 peptide were identified, one peptide bound in the active site and a second
peptide bound between the N-lobe and the C-lobe. We named this area, “secondary binding site,”
(SBS) since we found a second version of the PARP1 peptide.
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Figure 17. Substrate binding site.
A) 2Fo-Fc map of the PARP1 peptide in the substrate binding site was calculated at 2.1 Å and
contoured at 1.0 s. PARP1 peptide is shown as ball and sticks. (B) Surface-stick representation of
SMYD2-PARP1 complex. SMYD2 domains are colored according to Figure 16B. (C) Ribbon
alignment of previously structured peptides. PARP1, p53 and ERα peptides are colored in
magenta, blue and yellow respectively. K0 refers to the target lysine. L-1, G+1, and G+2 refer to
the amino acid positions flanking the target lysine.
Structure of the PARP1 peptides in the substrate and secondary binding sites
The PARP1 peptide in the substrate binding site has a similar structure as previously
reported p53 and ERα peptides [54, 57, 58]. The target lysine side chain sits inside the lysine
access channel which is created by F184, Y240 and Y258, and the carbonyl oxygen of target lysine
forms a hydrogen bond with T185 amide nitrogen. Leu-1 fits into a concave pocket formed by
V179, T185 and the main chain loop between αD helix and β8 strand. Gly+1 and Gly+2 mimic
the p53 and ERα peptide main chains. There is no electron density beyond Gly+2 and Leu-1 due
to the lack of an electron density map. This may suggest residues beyond these positions do not
significantly contribute towards binding to SMYD2; therefore, these resides were disordered in
the crystal. This explanation can be highlighted by a previous report that SMYD2 substrate
recognition is dependent on the P-1 and P+1 positions where P-1 must be leucine
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Figure 18. A second peptide identified in the C-terminal domain.
(A) Refined 2Fo-Fc map of the PARP1 peptide in the secondary binding site was calculated at 2.1
Å and contoured at 1.0 s. (B) Surface-stick representation of PARP1 (sky blue)and SMYD2 (red)
interaction in the secondary binding site. Amino acid positions Thr-2 through Arg-6 refer to the
positions flanking the target lysine in the PARP1 peptide (C) ITC of SMYD2 WT (red) and
SMYD2 L351A/W356 mutant (green). Top panel displays corrected heat injections data. Bottom
panel displays isotherm plot.
and the P+1 must be a small amino acid. Residues beyond these limits may aid in SMYD2 binding
but are not necessary as hinted by the lack of an electron density map (Figure 17A).
The PARP1 peptide in the secondary binding site is nested into a small fissure in the CTD
created by αJ, αK and αL. This interaction is hydrophobically driven by two residues in PARP1,
Leu-3 and Met-5. Leu-3 packs against residues W356, L391 and G394. Met-5 fits into a
hydrophobic crevice created by L351, K387, R390, and L391. An electron density map couldn’t
be mapped for the Lys-4 side chain which suggests Lys-4 adopts multiple orientations and doesn’t
significantly contribute towards SMYD2 binding (Figure 18A and B).
Two binding sites confirmed by Isothermal Titration Calorimetry.
In order to confirm two binding sites, ITC was performed to measure the stoichiometry
with high accuracy. Titration of the PARP peptide (RMKLTLKGGAAVD) into full length human
SMYD2 generated exothermic injections. Data was fit into an independent model with n = 2.21 ±
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0.28. Measured enthalpy and dissociation constant were -0.65 kcal/mol and 28 µM, respectively.
Calculated Gibb’s energy and entropy (-T∆S) were -6.4 kcal/mol and-5.8 kcal/mol, respectively.
The high entropic term, nearly nine fold higher than the enthalpic term, suggest peptide binding
between SMYD2 and PARP1 is hydrophobically driven. This observation is consistent with the
complex structure of SMYD2 and PARP1 peptides since both sides appear to be primarily driven
by hydrophobic contacts (Figure 2B and 3B).
To confirm the PARP1 peptide was specifically binding in the secondary binding site, we
mutated L351A and W356A in SMYD2 and purified it similarly as the wild type with no
observable complications in mutant solubility. The same ITC experiment was performed on
SMYD2 mutant (L351A and W356A.) Unexpectedly, no heat change was observed suggesting
PARP1 didn’t bind to the secondary binding site and substrate channel. This observation would
suggest peptide binding to the substrate binding site requires a peptide bound to the secondary
binding site. It’s unclear whether peptide binding is sequential where the peptide from the
secondary binding site is channeled to the active site or peptide binding in both sites are
independent. Sequential binding is conceivable as this could influence the TRP-like domain to
open the structure and tunnel the substrate towards the active site. Further work will be required
to evaluate possible links between the substrate and the secondary binding sites.
Discussion
Crystal structures of SMYD proteins demonstrate the N- and C-lobe can potentially change
[24, 35, 39]; however, the mechanism at which these lobes undergo bilobal conformational
changes remains elusive. Additionally, the mechanism at which SMYD2 methylation clients are
guided into the buried substrate channel is unclear. In this study, we found a peptide substrate
predominantly bound to an new and unexplored area of the CTD in our SMYD2-PARP2 complex
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crystal structure. Our ITC results demonstrate SMYD2 can bind to two PARP1 peptides; therefore,
the second peptide bound to the secondary binding site doesn’t appear to be a non-specific artifact.
Interestingly, titration of the PARP1 peptide into SMYD2 L351A/W356A mutant didn’t generate
heat suggesting the PARP1 peptide binding into the substrate channel may be sequential, requiring
PARP1 to bind to the secondary binding site first before PARP1 is guided into the substrate
channel.
To our knowledge, this study presents the first SMYD structure that binds a second peptide
outside of the substrate channel. We imagine this new peptide binding site may recognize a
hydrophobic motif (MXL or ΦXΦ) within a substrate protein or perhaps protein chaperone that
isn’t a SMYD2 methylation client. Hydrophobic motifs binding to the secondary binding site could
potentially change the dynamics of the C-lobe in SMYD2; thereby, allowing the substrate channel
to become more accessible for methylation targets to enter. Since purified human SMYD2
methyltransferase activity is low [61], we predict the secondary binding site as an allosteric
modulator that drives the C-lobe to open for substrate binding. To test this hypothesis, further work
will require measuring the activity of SMYD2 L351A/W356A mutant to understand how the
secondary binding site influences methylation of PARP1. At the moment, this study opens a new
avenue for understanding how SMYD2 methylation clients are recognized and tunneled for lysine
methylation.
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Table 1. Crystallographic data and refinement statistics
Data
Space group
C121
Cell parameters
a, b, c (Å)
142.8, 52.2, 144.9
Wavelength (Å)
0.97856
Resolution (Å)
133.2-2.10 (2.21-2.1)a
Rmergeb
0.105 (0.812)
CC1/2
0.995 (0.772)
Redundancy
7.3 (7.4)
Unique reflections
51097
Completeness (%)
88.5 (96.7)
13.7 (2.5)
〈I/σ〉
Refinement
Resolution (Å)
66.6-2.10 (2.14-2.10)
Molecules/AU
2
Rworkc
0.199 (0.246)
Rfreed
0.234 (0.293)
Ramachandran plot
Residues in favored
97.8%
Residues in allowed
2.2%
RMSD
Bond lengths (Å)
0.003
0.69
Bond angels (°)
No. of atoms
Protein
7290
Peptide
132
Water
154
B-factor (Å2)
Protein
43.8
Peptide
73.0
Water
33.9
a
Numbers in parentheses refer to the highest resolution
shell.
b

Rmerge= Σ|I-〈I〉| / ΣI, where I is the observed intensity
and 〈I〉 is the averaged intensity of multiple
observations of symmetry-related reflections.
c

Rwork= Σ|Fo-Fc| / Σ|Fo|, where Fo is the observed
structure factor, Fc is the calculated structure factor.
d

Rfree was calculated using a subset (5%) of the
reflection not used in the refinement.
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CHAPTER 5 EXPRESSION, PURIFICATION AND ACTIVITY STUDIES OF THE
CATALYTIC DOMAIN OF USP10
Introduction
Ubiquitin-specific protease 10 (USP10) is an widely expressed deubiquitinase that plays a
central role in maintaining p53 homeostasis, DNA repair and apoptosis [28, 141, 142]. USP10 was
first identified in associate with G3BP which served to inhibit the deubiquitinase function of
USP10. Later studies expanded USP10’s role as a specific deubiquitinase for p53, histone variant
H2A.Z, CFTR, AMPKα and FLT3 in various cellular pathways [28, 30, 142-145]. While the
biological mechanism of USP10 appears to be diverse, one pathway of interest is USP10’s
involvement in maintaining p53 homeostasis. One study found that USP10 serves dual roles as a
oncogene and tumor suppressor, depending on the oncogenic nature of p53. Under normal
physiological conditions, USP10 serves as a tumor suppressor by preserving p53 homeostasis and
counteracting p53 ubiquitination by Mdm2; however, in a p53 mutant environment, the role of
USP10 reverses to an oncogene by stabilizing oncogenic p53 [28]. Inhibition of USP10 through
RNA knockdown experiments greatly reduced cellular growth in mutant p53 renal cancer cells
[28, 30].
Alternatively, USP10 was also found to inhibit p53 function though a positive feedback
loop promoting androgen receptor-mediated transcription and G3BP expression. Since G3BP
serves as an inhibitor of USP10 function, this resulted in repressing p53 function and promoting
proliferation in G3BP2-overexpressed prostate cancer cells. Recently, USP10 was found to play a
key role in stabilizing mutant FLT3 in acute myeloid leukemia (AML) cells. Mutagenesis of
USP10’s catalytic activity (C424S) resulted in reduced stabilization of mutant FLT3 in MOLM14
cells [30]. Therefore, designing small molecule inhibitors that specifically target USP10 may prove
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to be a novel strategy for treating patients with mutant p53 cancers, mutant FTL AMLs and
androgen receptor-dependent prostate cancers.
Alas, the atomic structure of USP10 and selective inhibitors for USP10 are currently
lacking. One group identified two small molecule inhibitors that target USP10 activity in vitro;
however, these compounds also target a related p53 deubiquitinase, USP7 [146, 147]. Another
group identified spautin-1 as a selective inhibitor against USP10 and USP13 deubiquitinating
function [148]. Recently, a mutant ubiquitin variant was reported to specifically inhibit USP10 in
vitro which serves as an excellent aid to study USP10 for cellular and biochemical studies [149].
All of the USP10 inhibitors were reported by separate groups, and a collective study of these
inhibitors is needed.
In this study, we explore the biochemistry of the catalytic domain of human USP10 and
examine the potency of reported inhibitors: UbV10, spautin-1 and P22077. Our goal was to solve
the crystal structure of the catalytic domain of USP10 which would serve as a template for virtual
screening. In addition, comparing the inhibitory activity of reported inhibitors against USP10 can
aid in the development of a fragment-based screen to improve more potent and soluble inhibitors.
A selective inhibitor against USP10 would serve as a valuable tool to study USP10 overexpression
in oncogenic p53 cancers and oncogenic FLT3 acute myeloid leukemias.
Materials and Methods
Protein Expression and Purification
The core deubiquitinase catalytic domain of USP10 (S374 – L798) was cloned into pCDFSUMO vector and UbV10 construct was synthesized into pET151 vector (Invitrogen). Vectors
were transformed into BL21 (DE3) cells for recombinant protein expression. Cells grew to an
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optical density of 0.4 – 0.6 and protein expression was induced with 0.1 mM IPTG. Growth
continued overnight at 15°C. Harvested cells were suspended in binding buffer (20 mM sodium
phosphate, 500 mM NaCl, 5% glycerol, 20 mM imidazole, 5 mM BME) and lysed using a French
Press, and the supernatant was collected for purification. His6-SUMO-USP10(374-798) was
captured on a HisTrap column (GE Healthcare) and eluted out by applying a gradient of elution
buffer (20 mM sodium phosphate, 500 mM NaCl, 5% glycerol, 500 mM imidazole, 5 mM BME).
Fractions containing His6-SUMO-USP10-CA were pooled and dialyzed in binding buffer. Ulp1
was added to cleave off the His6-SUMO-USP10-CA tag. The native USP10-CA protein was
collected by passing the protein pool through the HisTrap column. Finally, USP10-CA was further
purified through a Superdex 200 column (GE Healthcare) into gel filtration buffer (20 mM Tris
pH 7.5, 150 mM NaCl, 5% glycerol, 5 mM BME). Fractions containing pure USP10-CA were
pooled, concentrated to 20 mg/mL and stored in the -80°C. UbV10 was purified similarly, except
the N-terminal His6 tag was removed by TEV protease.
Isothermal Titration Calorimetry
ITC titrations were carried out on a NanoITC SV calorimeter (TA Instruments) at 28°C
whilst stirring at 300 rpm. Experiments were performed with 23 (10 µL) injections spaced 300
seconds apart. The first (2 µL) injection was excluded from the data. USP10-CA and UbV10 were
dialyzed in the same buffer (20 mM HEPES pH 7.5, 150 mM NaCl) overnight. The sample cell
was loaded with approximately 1.2 mL of 25.5 µM USP10-CA, and the injection syringe was
loaded with approximately 230 µL of 283 µM UbV10. Protein concentrations were verified using
a Direct Detect (Millipore Sigma). Data was processed and fitted in NanoAnalyze (TA
Instruments).
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In vitro Deubiquitinase Activity Assay
Fluorescent activity assays were carried out on 384-well plates (Corning black flat/bottom)
using a SpectraMax M5 (Molecular Devices). Ubiquitin-Rhodamine 110 (Ub-Rho) was used as a
fluorescent substrate to monitor USP10-CA hydrolysis and liberation of Rhodamine 110. The final
reaction buffer was 50 mM HEPES 7.5, 0.5 mM EDTA and 5 mM DTT. A typical experiment
setup contained 200 nM USP10 and serial concentrations of Ub-Rho (0 – 30 µM) and UbV10 (0
– 10 µM) in a final volume of 25 (kinetic studies) or 30 µL (inhibitory IC50/Ki studies). USP10CA, UbV10, P22077 and Ub-Rho were diluted in reaction buffer and incubated at 30°C for at least
10 minutes. Fluorescence readings were recorded for 2 hours. Initial velocity was measured for
the first 5 minutes. Data was fit in GraphPad.
Results
Cloning and Purification of the catalytic domain of USP10.
The full length USP10 protein was previously expressed and purified in E.Coli with no
success [143]. Since we are specifically interested in the inhibition of USP10 deubiquitinase
function, we sought to localize and purify the catalytic core of USP10 using E.Coli as a production
host. In order to correctly define and clone USP10-CA, a sequence alignment was made across
select, structured USP homologs and USP10 orthologs using COBALT and ESPript (Figure 19A
and 19B) [150, 151].
In addition, a homology model of USP10-CA was made using SWISS-MODEL using
USP8 (PDB ID: 5N3K) as a template with a sequence identity of 26% [120]. The overall structure
and catalytic mechanism of USP10 should be expected to be similar to other USPs due to the
homogenous spread of conserved residues within the model (Figure 19C). USP10 is highly
conserved among orthologs; therefore, we designed the USP10-CA construct from S374-L798 that
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Figure 19. Sequence alignment of USP homologs and USP10 orthologs
(A) Sequence alignment of select USP homologs and (B) Sequence alignment of USP10 orthologs.
Identical residues are highlighted in red in white font. Positive residues are boxed in red font. (C)
SWISS model of USP10 using USP8 as a model base. Unstructured loops were excluded from the
model. Conserved residues among select USP homologs are colored in magenta. Outlined box:
Proposed mechanism for USP10 hydrolysis. (D) Open reading frame of human USP10.
incorporated most of the conserved regions within the active catalytic domain. After we
successfully cloned and purified our catalytic domain construct, a separate group also reported
purifying a similar USP10-CA construct, K376 – L798. [30].
The catalytic domain was expressed and purified using His6-SUMO fusion tag adjacent to
the N-terminal end of USP10. After capturing His6-SUMO USP10-CA from Ni2+ column, the
fusion tag was successfully removed from USP10-CA using Ulp1 protease. Several additional
purification steps were needed to prepare the protein pool for a second round pass through the Ni2+
column, and we were able to separate the His6-SUMO tag from USP10-CA (Figure 20A). USP10CA was injected into a size exclusion column and eluted out homogeneously as a ~50 kDa
monomer (Figure 20B) Altogether, soluble USP10-CA was obtained with high purity (Figure
20C).
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Figure 20 USP10 catalytic domain purification
(A) SDS-PAGE of SUMO-tag purification. 1: Pooled eluted fractions from containing His6SUMO-USP10-CA. 2: Supplementing Ulp1 protease cleaved into USP10-CA and His6-SUMO. 3|
Sample after concentrating protein pool. 4: Sample after filtration. 5: Sample after dialysis to
binding buffer. 6|:Pooled flowthrough and wash fractions after injecting the protein pool into a
second HisTrap pass. (B) HiLoad 16/60 chromatogram of USP10-CA. USP10-CA elutes out as a
homogenous monomer. (C) SDS-PAGE of the final purification product of USP10-CA.
In order to structure USP10-CA, we sought to crystallize USP10-CA, but our efforts to
obtain well-ordered crystals were unsuccessful. Possible crystallization complications could arise
due to large and distorted loop insertions (Figure 19A). To our knowledge, only four USP catalytic
domains have been crystallized in the apo form, solved and deposited in the PDB. Most of the USP
proteins are crystallized and structured as a complex with ubiquitin or a ubiquitin-derivative. This
observation suggests the catalytic domains of USPs are challenging to crystallize. One possible
explanation could be due to the conformational fluidity between active and inactive states
as observed from the apo structures of USP7, USP8 and USP14 [152-154]. When USPs are bound
to ubiquitin, this could limit the USP’s conformational state and aid in protein crystallization. We
sought to crystallize USP10-CA in complex with ubiquitin molecule in order to stabilize USP10
into a single conformation and promote our chances for USP10-CA crystallization.
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Figure 21. UbV10 complexes with USP10 catalytic domain
(A) GST-Ubiquitin pulldown of USP10-CA. (B) His-UbV10 pulldown of USP10-CA. (C) Gel
filtration chromatogram of USP10-CA and UbV10. (D) SDS-PAGE of fractions under the
chromatogram from C.
USP10-CA forms a complex with ubiquitin variant 10, not ubiquitin
Another challenge is complexing USP to ubiquitin since most USPs don’t bind strongly to
wild type ubiquitin. In order to structure USP and ubiquitin complexes, several groups covalently
link the USP of interest with a covalent linker, attached to the carboxyl end of ubiquitin as a tactic
to irreversibly link ubiquitin to the catalytic cysteine in USPs [152, 153, 155, 156]. An alternative
strategy are the use of ubiquitin variants which are generated through phase-display libraries of
mutated ubiquitin proteins [157]. The same group reported a mutated ubiquitin variant that
specially binds and inhibits full length USP10 [149]. We obtained the reported protein sequence
for UbV10, and purified UbV10 similarly as USP10 (data not shown). Consistently, we show
USP10-CA binds strongly to UbV10 but not ubiquitin (Figure 21A and B). This suggests the
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mutants created by phage display are important and necessary for USP10 binding. (Figure 21A
and 21B). In addition USP10-CA and UbV10 appear to stability complex under gel filtration
separation (Figure 21C and Figure 21D).
USP10 and UbV10 binding is strongly enthalpically driven
We next sought to measure the magnitude of binding (KD) as well as additional
thermodynamic information between USP10 and UbV10 by employing ITC. Measured enthalpy
and dissociation constant were -13.4 kcal/mol and 984 nM, respectively. Calculated Gibb’s free
energy (∆G) and entropy (-T∆S) were -8.3 kcal/mol and 5.1 kcal/mol, respectively. Overall, the
binding between USP10 and UbV10 is a favorable process as indicated by enthalpy and Gibb’s
free energy; however, the interaction between USP10 and UbV10 is not entropically favorable.
The high enthalpy and low entropic value suggest the interaction between USP10 and UbV10 are
favorably driven by forming hydrogen bonds and resisted by unfavorable structuring of USP10
and UbV10.
USP10-CA activity is low, and Spautin-1 doesn’t inhibit USP10-CA
To measure USP10-CA activity and inhibitory potency of UbV10, a fluorescence-based
activity assay using Ubiquitin-Rhodamine 110 (Ub-Rho) as a substrate was employed. USP10
hydrolysis activity is weak compared to other DUBs [149] since we were unable to reach velocity
saturation in our Michaelis-Menten curve. This is likely due to the high Michaelis constant (KM)
~14.3 µM for substrate, which suggests USP10 doesn’t bind strongly to the Ub-Rho. A separate
group reported low activity for full length USP10 using Ub-Rho as a substrate (KM >4 µM) [149].
Supplementation of UbV10 (1:20 molar protein:inhibitor) greatly diminished USP10-CA activity
and greatly enhanced the modeled KM. The modeled Vmax between USP10-CA and USP10-CAUbV10 were measured to 1.1 RFU/sec and 0.885 RFU/sec, respectively. The modeled Vmax and
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Figure 22. USP10-UbV10 binding is enthalpically driven and UbV10 competitively inhibits
USP10.
(A) ITC data of USP10-CA and UbV10. Top panel displays corrected heat injections. Bottom
panel displays isotherm plot. (B) Michaelis-Menten graph of USP10 activity. (C) Log-scale
inhibition curve of UbV10 and spautin-1 against USP10-CA activity.
KM parameters between USP10-CA alone and USP10-CA-UbV10 suggest UbV10 acts as a
competitive inhibitor against USP10-CA. Additionally, we sought to compare how and how well
UbV10 and spautin-1 inhibit USP10-CA. Our results indicate that spautin-1 doesn’t directly inhibit
USP10-CA. This finding is in conflict with another study which proposed spautin-1 selectively
inhibits USP10 activity [148]. Further investigation will require either testing spautin-1 against
full length USP10 or identifying an optimally active form of USP10. We were unable to detect
P22077 inhibitory activity against USP10-CA (data not shown) since the compound was insoluble
in our reaction buffer. Experiment will need to be repeated to accommodate the compound’s poor
solubility.
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Discussion
In this study, we supply biochemical and structural studies for the catalytic domain of
USP10 to pave the way for future drug development studies. We successfully purified the catalytic
domain of USP10 using E.Coli as a production host eliminating the need to use other expensive
expression systems; however, our E.Coli purified USP10-CA construct has low hydrolysis activity
in vitro. Previous studies also report low deubiquitination activity for full length USP10 [149].
Therefore, USP10 hydrolysis activity is likely dependent on post-translational modifications and
other protein chaperones like Beclin-1 [148]. Interestingly, USP10 is a phosphorylation target for
ATM kinase signaling, AMPKα and CKII kinase [28, 145, 158]. Indeed, two separate studies
found phosphorylation of USP10 S76 by AMPKα and USP10’s association with Beclin-1
promoted deubiquitinase activity [145, 148]. Future studies may benefit exploring how
phosphorylation and other protein chaperones influence USP10’s deubiquitination activity.
We also provide supporting evidence that UbV10 is an effective competitive inhibitor
against USP10-CA. The measured dissociation constant from our ITC results and inhibitory
constant from our activity data are in fair agreement, 984 nM and 766 nM respectively. The
thermodynamic binding profile of USP10-UbV10 appears to be similar to the thermodynamic
profile reported for USP7 and Ub25 [159]. Despite the favorable enthalpic yield of USP10 and
UbV10 binding, this complex outputs a disruptive entropic cost, which suggests the structuring of
USP10 and UbV10 as a complex is an unfavorable process.
In summary, our study presents a soluble catalytic domain construct for human USP10
which is viable for further biochemical studies. Our data supports UbV10 as an active inhibitor
against USP10-CA and may prove to be a useful as a tool to stabilize and potentially crystallize
USP10. Unexpectedly, we did not observe significant inhibitory activity for spautin-1 which
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suggests spautin-1 doesn’t target the active site of USP10. Further studies towards developing
small and selective molecule inhibitors for USP10-CA will require robust target-based chemical
screening and understanding how USP10 achieves optimal biochemical activity. Attaining a high
resolution structures of USP10 would also be of value since USP10 appears to be a fairly unique
structure based on the lack of sequence conservation from other deposited USP structures. We
look forward to future reports that dissect the structure and function USP10.
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CHAPTER 6 STRUCTURAL BASIS OF PDZ-MEDIATED CHEMOKINE RECEPTOR
CXCR2 SCAFFOLDING BY GUANINE NUCLEOTIDE EXCHANGE FACTOR PDZRHOGEF
*Published in Biochem Biophys Res Commun. 2017 Apr 1;485(2):529-534. doi:10.1016/
j.bbrc.2017.02.010. All authors agreed with including their work in this dissertation.
Introduction
CXCR2 is a G protein coupled receptor important for cellular mobility and chemotaxis
through activation of calcium mobilization and actin polymerization [33]. CXCR2 is central to
neutrophil migration to sites of inflammation and involved in wound healing and angiogenesis
[33]. It has been shown that disrupting CXCR2 function plays a central role in multiple
inflammatory diseases including rheumatoid arthritis, acute respiratory distress syndrome, septic
shock, and chronic obstructive pulmonary dis- ease, likely due to the result of excessive release of
neutrophils from the bone marrow [160]. CXCR2 also plays a critical role in many cancers such
as lung cancer and pancreatic cancer by promoting tumor invasion and metastasis via autocrine
and paracrine effects [161]. Elevated expression of CXCR2 enhances cancer cell proliferation and
survival and often correlates with aggressive stages of cancer and poor overall prognosis [161].
CXCR2 directing cell trafficking depends on its ability to bind to ELR-positive CXC
chemokines [162]. When binding to a chemokine, CXCR2 is capable of initiating G protein
dissociation and inducing downstream signaling cascades that drive cell movement along
chemokine concentration gradients. However, swift signaling requires direct and indirect
interaction of CXCR2 with other membrane receptors, channels, intracellular scaffold proteins,
effectors, and cytoskeletal elements, among which PDZ domain- containing proteins play a central
role in efficient signaling by scaffolding the formation of macromolecular complexes at the plasma
membrane and functionally coupling chemokine signaling to downstream signaling events [33].
In general, PDZ domains mediate protein interaction by recognizing the C-terminal sequence of
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target proteins and binding to the targets through a canonically and structurally conserved PDZ
peptide-binding pocket [163]. The specificity of the interaction is determined mainly by the
residues at positions 0 and 2 of the peptides (position 0 referring to the C-terminal residue),
whereas other residues do not significantly contribute to the interaction. As a result, PDZ domains
are highly promiscuous capable of binding to multiple ligands; single peptides are capable of
binding to distinct PDZ domains. Because of this promiscuity, PDZ-mediated interaction can
generate complex and interconnected signaling networks that ensure precise and efficient signal
transduction via protein-protein interaction.
However, the canonical ligand-binding of PDZ by itself has a limited capacity to scaffold
multiprotein arrays within membrane microdomains, as PDZ domains can only bind to their
ligands one at a time. Recent data suggest that PDZ dimerization plays an important role in
increasing the scaffolding capacity [164]. PDZ dimerization with the same or different PDZcontaining proteins has been shown to amplify the complexity of interacting proteins in signal
transduction networks and provide a mechanism to expand the scaffolding capacity in the assembly
of multiprotein complexes. Of note, many PDZ domains can dimerize and 30% out of 150 PDZ
domains in the mouse genome has been shown to participate in protein-protein interaction [165].
This suggests PDZ domains have evolved as a dual binding module in facilitating complex
formation. Therefore, there has been a considerable interest in elucidating the structural basis of
PDZ specificity, promiscuity and dimerization and how they can set up a specific interaction
network for proper signaling, the nature of which still remains obscure.
Recently, we showed that the PDZ domains of NHERF1 play a pivotal role in CXCR2
signaling during the formation of macromolecular signaling complexes[33, 161]. NHERF1
scaffolds the interaction between CXCR2 and PLCβ2/3 by simultaneously binding to the C-
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terminal tail of CXCR2 and PLCβ2/3 and physically connecting them through linked PDZ
domains or PDZ dimerization. This resulted in a macromolecular complex essential for coupling
CXCR2 activation to PLCβ2/3 signaling cascades in neutrophils and pancreatic cancer cells.
Disruption of the interaction effectively abolished chemotaxis and transepithelial migration
suggesting a functional importance of PDZ-mediated scaffolding. However, NHERF1 is the only
PDZ domain-containing protein identified to date to interact with CXCR2. As a result, there is a
limited understanding regarding the molecular mechanism of CXCR2 PDZ-binding promiscuity
and how binding to different PDZ domains may interconnect different signaling pathways in
CXCR2 signaling.
In this study, we sought to identify additional PDZ domains that could interact with the
PDZ motif of CXCR2 and to better under- stand PDZ binding promiscuity and specificity. We
identified several novel CXCR2 binding proteins using a PDZ binding array, among which PDZRhoGEF is of particular interest because it is also involved in signaling and cellular mobility. PDZRhoGEF is a PDZ and RGS-containing protein and belongs to the guanine nucleotide exchange
factors family. It is a protein ubiquitously expressed in humans and involved in initiating the Rho
signaling pathway for actin organization and cellular mobility [166]. To understand the molecular
mechanism of CXCR2 PDZ motif binding to the PDZ domain of PDZ-RhoGEF, we solved the
crystal structure of PDZ- RhoGEF PDZ domain in complex with the CXCR2 C-terminal PDZ
binding motif. The structure reveals that the CXCR2 peptide binds to PDZ in an extended
conformation with the last four residues making specific side chain contacts. Sequence alignment
and structural comparison analyses suggest the sequence- and position-specific interactions
determine CXCR2 PDZ-binding promiscuity and specificity. Unexpectedly, we identified a
disulfide bond-linked PDZ dimer which enables parallel binding of CXCR2 peptides to the well-
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separated ligand-binding pockets. This new mode of PDZ dimerization demonstrates structural
diversity in PDZ-PDZ interaction and could prove valuable for understanding the complexscaffolding function of PDZ-RhoGEF in CXCR2 signaling.
Materials and Methods
2.1 PDZ domain array screen
CXCR2-binding PDZ domains were screened using TranSignal PDZ Domain Array IV
(Panomics) according to the manufacture's instruction. His-tagged C-terminal fragment of human
CXCR2 (residues 316-360) was used in the assay screen, which was generated by PCR cloning
into pET30 and purified using cobalt resins [33]. The purified CXCR2 was incubated with the
PDZ Domain Arrays in blocking buffer for 1 h at room temperature, and washed thrice with wash
buffer for 5 min. They were then incubated with Anti-histidine horseradish peroxidase (HRP)
conjugate for 1 h at room temperature. Antibody complexes were detected by enhanced
chemiluminescence and imaged using BioSpectrum 500 (UVP). The array was repeated twice and
similar results were observed.
2.2 PDZ protein expression and purification
The cDNA fragment of human PDZ-RhoGEF PDZ (residues 41-123) was cloned into a
pSUMO vector containing an N-terminal His6-SUMO tag. The C-terminal extension TSTTL that
corresponds to residues 356-360 of human CXCR2 was included in the reverse primer to create a
chimeric clone. The clone was transformed into Escherichia coli BL21 Condon Plus (DE3) cells
for protein expression. The transformants were grown to an OD600 of 0.4 at 37°C in LB medium,
and then induced with 0.1 mM isopropylthio-β-D-galactoside at 15°C overnight. The cells were
harvested and lysed by French Press. The soluble fraction was then subjected to Ni2+ affinity
chromatography purification, followed by cleavage the His6-SUMO tag with yeast SUMO
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Protease 1. PDZ proteins were separated from the cleaved tag by a second Ni2+ affinity
chromatography and further purified by size-exclusion chromatography. Finally, the proteins were
concentrated to 10 mg/ml in a buffer containing 0.1 M sodium acetate pH 4.8., 150 mM NaCl, 5
mM b- mercaptoethanol (BME), and 5% glycerol.
2.3. Crystallization, data collection and structure determination
Crystals were grown by the hanging-drop vapor-diffusion method by mixing the protein
(~10 mg/ml) with an equal volume of a reservoir solution containing 0.1 M sodium acetate pH 4.6,
0.1 M sodium citrate, 25% PEG8000 at 20°C. Crystals were cryoprotected in a solution containing
20% glycerol. Crystal data were collected at 100 K at the Advanced Photon Source (Argonne, IL)
at beamline 21- ID-D and processed and scaled using XDS [136]. Crystals belong to the space
group C2221 with four molecules in the asymmetric unit (Supplementary data). The structure was
solved by molecular replacement using PDZ-RhoGEF PDZ-PlexinB2 structure (PDB code: 5E6P)
as a search model. Structure modeling was carried out in COOT [138] and refinement was
performed with PHENIX [139]. The final model was analyzed and validated with Molprobity
[139]. All figures of PDZ-CXCR2 structure were made with PyMOL.
2.4 Protein data bank accession number
Coordinates and structure factors have been deposited in the Protein Data Bank with
accession number 5TYT.
Results
3.1 CXCR2 C-terminus binds directly to PDZ-RhoGEF PDZ domain
Using a PDZ Array screen (Panomics), the CXCR2 C-terminus was identified to directly
bind to the PDZ domains of PDZ-RhoGEF, leukemia associated RhoGEF (LARG), disks large
homolog 3 (DLG3-D2), alpha-1-syntrophin (SNA1) and SH3/multiple ankyrin repeat domains
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protein 1 (SHANK1) (SHK1) (Fig. 1A). DLG3-D2 is the second PDZ domain in synapseassociated protein 102 which serves as a post-synaptic scaffold for glutamate receptor signaling in
developing cortical neurons. SNA1 is the only PDZ domain in alpha-1-syntrophin which serves as
a scaffold for dystrophin protein complexes in Rac1 signaling in skeletal muscles. SHK1 is the
first PDZ domain in SHANK1, a scaffolding protein that clusters neurotransmitter receptors
necessary for synapse changes and development. PDZ-RhoGEF and LARG were of interest due
to their imperative roles in cellular signaling and mobility [166], an analogous function of CXCR2.
PDZ-RhoGEF and LARG possess one PDZ domain and were known to bind to PlexinB1/2,
LPA1/2, and insulin-like growth factor-1 receptor in addition to CXCR2 [166]. These together
raise an interesting question regarding the mechanism of how CXCR2 is recognized by different
PDZ domains and how PDZ-RhoGEF PDZ binds to different substrates.
3.2 Binding specificity of the PDZ-CXCR2 interaction
To understand the interaction between PDZ-RhoGEF and CXCR2, we solved the crystal
structure of PDZ-RhoGEF PDZ in complex with the C-terminal sequence (TTSTL) of CXCR2.
The overall structure of PDZ-RhoGEF PDZ is similar to other PDZ domains [163], consisting of
six β strands (β1-β6) and two α-helices (αA and αB) (Fig. 1B). The CXCR2 peptide binds in the
cleft between β2 and βB, burying a total solvent-accessible surface area of 507.4 Å2. The binding
specificity of the PDZ-CXCR2 interaction is achieved through networks of hydrogen bonds and
hydrophobic interactions (Fig. 1C). At the ligand position 0, the side chain of Leu0 is nestled in a
deep hydrophobic pocket formed by conserved residues Phe57, Phe59 and Val61 from β2 and
Val106 and Ile109 from αB (Fig. 1D). In the pocket, the position of Leu0 is further secured by
both a hydrogen bond from its amide nitrogen to the Phe59 carbonyl oxygen and bifurcated
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Figure 23. Structure of PDZ-RhoGEF PDZ (rPDZ) in complex with the CXCR2 Cterminal sequence TSTTL.
(A) PDZ Array screen of CXCR2-binding PDZ domains. Kv1.4 serves as a positive control for
PDZ-peptide binding, and GST alone a negative control. (B) Ribbon diagram of rPDZ-CXCR2
structure. The PDZ is shown in blue and CXCR2 in magenta. Secondary structures are numbered
and labeled based on their sequence position. (C) Detailed view of the PDZ ligand-binding site.
2Fo-Fc omit map of CXCR2 peptide was calculated at 2.4 Å and contoured at 1.0 s. Hydrogen
bonds are illustrated as yellow broken lines. (D) Sequence alignment of CXCR2-binding PDZ
domains. Identical residues are represented as white on black and similar residues are colored in
cyan. Residues important for binding to CXCR2 are indicated by asterisks. The secondary structure
elements are labeled according to 1B.
hydrogen bonding between the Leu0 carboxylate and the amides of Phe57 and Gly58. Similar
interactions have been observed in several other PDZ-mediated complexes which represent the
most-conserved binding mode for terminal leucine recognition [163]. Residues at other peptide
positions also contribute to the PDZ-CXCR2 complex formation. At position 1, the side chain
hydroxyl of Thr-1 forms a hydrogen bond with the Og1 atom of the Thr60 side chain. At position
2, Thr-2 makes one hydrogen bond to the His102 imidazole group and two hydrogen bonds to the
highly conserved residue Val61. At the ligand position 3, the interactions with Ser-3 include one
hydrogen bond from its side chain hydroxyl to the Oε1 atom of Gln70, and a VDW interaction
with the side chain of Ser62. Finally, the peptide residue Thr-4 engages in a main-chain contact
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with Gly63, but does not participate in any specific side-chain interactions. These observations
indicate that the last four residues of CXCR2 contribute to the binding specificity in the PDZCXCR2 complex formation.
3.3 CXCR2 and PDZ binding promiscuity
To gain insight into promiscuous CXCR2 binding by different PDZ domains, we compared
the structures of all available PDZ domains in complex with CXCR2, including NHERF1 PDZ1,
NHERF1 PDZ2 and current PDZ-RhoGEF PDZ (rPDZ)[163, 167]. We also compared the rPDZCXCR2 structure to the structure of rPDZ in complex with a PlexinB2 peptide in order to
understand PDZ binding promiscuity. These liganded PDZ structures are very similar with
pairwise root-mean-square differences (RMSDs) ranging from 0.47 to 0.87 Å for entire C atoms
(Fig. 2A). The main chains of the bound peptides superimpose well, as do their relative spatial
positions to the conserved PDZ motifs. Additionally, the ligand recognition modes at the peptide
positions 0 and 2 are virtually indistinguishable, characterized by structurally similar binding sites
composed with highly conserved residues (Fig. 2B). This observation is consistent with previous
evidence that the 0 and 2 residues of the ligand are critical for determining the binding specificity
and affinity of PDZ-peptide interaction [163].
Large differences were found in ligand recognition at the peptide positions 1 and 3. In
CXCR2-binding PDZ domains, residues that recognize these two positions are not conserved; in
fact, the residues that recognize the 3 position are not even structurally equivalent (Figs. 1D and
2B). At position 1, the binding conformation of Thr-1 is nearly identical in different PDZ
structures. The side chain of Thr-1 is oriented towards the same direction facing a residue
equivalent to rPDZ Thr60. As a result, Thr-1 is recognized by different residues from the
equivalent position. In NHERF1 PDZ1, the side chain hydroxyl of Thr-1 is stacked by the
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Figure 24. Structural comparison between PDZ-ligand complexes.
(A) Superposition of rPDZ-CXCR2 (blue), rPDZ-PlexinB2 (green), NHERF1 PDZ1-CXCR2
(pink) and NHERF1 PDZ2-CXCR2 (orange). PDZ domains are represented by ribbon, and
ligand residues are displayed as sticks. (B) Superposition of PDZ ligand-binding sites. Colors are
identical from 2A. (C) Sequence alignment of last five residues of known rPDZ binding targets.
imidazole ring of a histidine residue. In NHERF1 PDZ2, the side chain hydroxyl of Thr-1 forms a
hydrogen bond with the side chain nitrogen of an asparagine. In current rPDZ structure, the
equivalent hydroxyl group forms a hydrogen bond to the side chain of Thr60. In SHK1 and DLG3D2, Thr-1 may interact with a valine and serine respectively (Fig. 1D). This demonstrates Thr-1
can be recognized by different residues via different interactions without the need for significant
structural changes. This is also consistent with previous data that 1 residue in the peptide ligands
is less stringently specified by individual PDZ domains than the residues at the 0 and 2 positions,
thereby allowing binding promiscuity [163].
At position 3, the peptide binding is more PDZ specific, facilitated by the rotameric
flexibility of Ser-3 (Fig. 2B). In the binding, Ser-3 adopts different rotamers and each rotamer is
able to bind to a unique position in PDZ domains. In NHERF1 PDZ1, the side chain hydroxyl of
Ser-3 points to the N-terminus of the peptide forming a hydrogen bond to a histidine residue at the
receptor position 1. In NHERF1 PDZ2, the side chain hydroxyl of Ser-3 points towards the Cterminus forming a hydrogen bond to an asparagine at the receptor position 2. In current rPDZ, the
pointing direction of the Ser- 3 side chain is perpendicular to the peptide direction which enables

93
hydrogen bonding with a glutamine residue at the receptor position 3. Of note, all these receptor
positions have been suggested to contribute to a high degree of selectivity in PDZ ligand
recognition and the ability for the PDZ domain family to bind to different sequences [168]. The
present study is extending the role of these receptor positions in determining binding diversity, and
the fact that one of such positions can be specifically selected for interacting with 3 residue makes
it possible for different PDZ domains to recognize the ligand residues of same sequence, providing
an explanation for promiscuous CXCR2 binding.
The structural comparison between rPDZ-CXCR2 and rPDZ-PlexinB2 provides some
insight into PDZ binding promiscuity. The residues at the ligand positions 1 and 3 are highly
variable across rPDZ binding targets (Fig. 2C) indicating an ability of rPDZ to bind to ligands with
different 1 and 3 side chains. At position 1, Thr-1 of CXCR2 forms a hydrogen bond with Thr60,
whereas most of the side chain atoms of Asp-1 in PlexinB2 are disordered suggesting no stable
interaction between Asp-1 and rPDZ; and the 1 position of PlexinB2 may not significantly
contribute to the binding specificity (Fig. 2B). At position 3, Val-3 of PlexinB2 forms less
discriminative VDW interactions with Gln70 and Ser62, differing from Ser-3 of CXCR2 which
forms a specific hydrogen bond with Gln70. This difference indicates that rPDZ is able to form
different types of interactions with 3 residues, which may underlie its flexibility to accommodate
ligands with different 3 side chains.
3.4. Disulfide bond linked PDZ dimer
The most intriguing finding in current rPDZ structure is an asymmetric disulfide bondlinked PDZ dimer found in the asymmetric unit of the crystal (Fig. 3A). PDZ dimerization has
been well appreciated as an important mechanism for improving PDZ scaffolding capacity during
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Figure 25. Disulfide bond linked PDZ dimer.
(A) Overall view of PDZ dimer (side view, left; top view, right). (B) Close-up view of the dimer
interface. 2Fo-Fc omit map of the disulfide bond was calculated at 2.4 Å and contoured at 1.0 s.
(C) SDS-PAGE of 5 µg of rPDZ-CXCR2 fusion protein with/without BME.
the formation of multiprotein complexes [165]. The dimerization is usually formed by noncovalent PDZ-PDZ interactions that put two canonical binding sites in a close proximity to
facilitate a parallel or antiparallel nucleation of interacting proteins. However, the nature and
significance of the less common disulfide bond-linked dimers remain largely elusive, though a few
studies have suggested that the formation of disulfide bonds between proteins can be triggered by
reactive oxygen species during cellular signaling [169]. In current rPDZ structure, two Cys47 on
the outer surface of the b1 strand form an intermolecular disulfide bond responsible for PDZ
dimerization (Fig. 3A). The dimer is an asymmetric dimer with the upper side having a pseudo 2fold symmetry generated by parallel stacking of two copies of strands b1 and b6, and the lower
side being asymmetric generated by the interaction between αA and β4 from different monomers.
The buried surface area at the dimer interface is 777.6 Å2.
In addition to the disulfide bond, the dimer interface is further stabilized by several
hydrogen bonds and hydrophobic interactions (Fig. 3B). At the upper side of the interface, there
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is a continuous hydrophobic core formed by pairs of residues Ile49, Tyr114 and Ala116, which is
located above the disulfide bond bridge. At the lower side of the interface, two asymmetric
hydrogen bonds are formed: Lys91 from the β4-β5 loop in monomer A forms a hydrogen bond
with Ala81 carbonyl oxygen from the αA helix in monomer B; Lys80 from the αA helix from
monomer B forms a hydrogen bond with Asn93 carbonyl oxygen from the β4-β5 loop in monomer
A. Of note, all these residues including the disulfide bond forming residue Cys47 are highly
conserved in the PDZ and RGS-containing GEF protein family suggesting a conserved function
of this disulfide bond-linked dimer (Fig. 1D). Reducing SDS-PAGE indicates that the disulfide
bonds contribute to the formation of a dimer in solution (Fig. 3C). Previous studies have also
demonstrated that rPDZ dimerization linked by Cys47 disulfide bond regulates the canonical
ligand binding and enhances in vitro binding to a bivalent PlexinB2 PDZ motif [34].
Discussion
In this study, we identified several CXCR2 interacting PDZ domains including PDZRhoGEF PDZ. We solved the crystal structure of PDZ-RhoGEF PDZ in complex with the CXCR2
C-terminal tail that provides the molecular basis of the interaction. The crystal structure also
reveals an unexpected asymmetric disulfide bond-linked PDZ dimer that allows simultaneous
parallel binding of CXCR2 to two PDZ domains. While the functional link between CXCR2 and
PDZ-RhoGEF in signaling and cellular mobility requires future investigation, the identification of
new CXCR2-binding PDZ domains is enforcing the view that PDZ domains play important roles
in CXCR2 signaling processes capable of scaffolding complex interaction networks and coupling
CXCR2 signaling to specific signaling pathways, potentially Rho signaling and Rac1 signaling
through interacting with PDZ-RhoGEF and SNA1 respectively [166]. The identified interactions
also provide additional models that enable further understanding of PDZ and CXCR2 binding
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promiscuity and specificity. The structural comparison is able to reveal the residues at the ligand
positions 1 and 3 conferring PDZ- and ligand-specific recognition that may underlie the ability of
CXCR2 to be bound by different PDZ domains and PDZ-RhoGEF PDZ to bind to different
ligands. Additionally, the finding of the unexpected disulfide bond-linked PDZ dimer further
demonstrates the structural diversity of PDZ dimerization. Diverse PDZ-PDZ interactions have
been optimized as a mechanism in scaffolding the formation of distinct multiprotein complexes
[165]. This non-canonical binding mode has been suggested to contribute more to defining the
precise composition of protein complexes than does the canonical binding mode due to the
structural diversity [165]. Therefore, there has been a continuous interest in revealing the specific
nature of PDZ-PDZ interactions and their selectivity in precise scaffolding of temporal and spatial
signaling networks. The current study provides an additional example of how PDZ domains may
dimerize, and the asymmetric interface and rare disulfide bond linkage effectively define a new
mode of PDZ dimerization, which is different from any reported structures [163]. Together with
PDZ binding promiscuity, the new mode of dimerization could provide a reactive oxygen speciessensitive molecular scaffold for assembly of distinct CXCR2 signaling networks in actin
polymerization and cell mobility.
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Table 2. Crystallographic data and refinement statistics
Data
Space group
C2221
Cell parameters
a, b, c (Å)
61.7, 66.6, 168.4
Wavelength (Å)
1.07822
Resolution (Å)
84.2-2.40 (2.44-2.40)a
Rmergeb
0.094 (0.738)
Redundancy
6.5 (6.1)
Unique reflections
13997
Completeness (%)
99.9 (99.2)
11.2 (2.2)
〈I/σ〉
Refinement
Resolution (Å)
43.7-2.40 (2.44-2.40)
Molecules/AU
4
Rworkc
0.206 (0.303)
Rfreed
0.243 (0.356)
Ramachandran plot
Residues in favored
98.0%
Residues in allowed
2.0%
RMSD
Bond lengths (Å)
0.009
1.19
Bond angels (°)
No. of atoms
Protein
2619
Peptide
144
Water
13
B-factor (Å2)
Protein
64.6
Peptide
70.7
Water
51.5
a
Numbers in parentheses refer to the highest resolution
shell.
b

Rmerge= Σ|I-〈I〉| / ΣI, where I is the observed intensity
and 〈I〉 is the averaged intensity of multiple
observations of symmetry-related reflections.
c

Rwork= Σ|Fo-Fc| / Σ|Fo|, where Fo is the observed
structure factor, Fc is the calculated structure factor.
d

Rfree was calculated using a subset (5%) of the
reflection not used in the refinement.
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X-ray crystallography is the gold standard method for imagining macromolecules to atomic
resolution. Three dimensional data is central to understanding the molecular mechanism how
DNA, RNA and proteins function in biological events. Structural insights into these events
provide a molecular window to visualize how biological molecules influence human health.
Visualizing the architecture of these molecules set the stage for rational and selective drug design.
The following dissertation utilizes biochemical and biophysical tools, including X-ray
crystallography, to shed light on poorly understood mechanisms related to SMYD2 activity and
regulation, USP10 architecture and function, and PDZ-RhoGEF dimerization.
SMYD2 is one member of the SET and MYND domain-containing protein (SMYD) family
known to play key roles in cardiac function and development, innate immunity and tumorigenesis.
While the molecular pathways involved in these events have been fairly described, the molecular
mechanism of substrate recognition and bilobal changes have not. In this dissertation, I review the
structure and function of SMYD protein family. In addition, I demonstrate SMYD2 and SMYD3
can exist in open and closed conformations based on X-ray crystallography, small angle X-ray
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scattering, and molecular dynamic simulations data. Lastly, I revealed a novel binding site in
SMYD2 that appears to be the first recognition site for SMYD methylation clients.
USP10 is one member of the ubiquitin-specific protease family important for DNA repair
and apoptosis by recycling cytosolic p53. However, in the mutant p53 environment, USP10 serves
as an oncogene; thereby promoting mutant p53-dependent cancer cell growth. Additional studies
found related USP10 oncogene roles in other cancers. Unfortunately the biochemistry and structure
of USP10 hasn’t been thoroughly explored. My dissertation aims to understand the biochemistry
and architecture of the catalytic domain of USP10 along with reported USP10 inhibitors which
would be valuable for future studies to probe USP10 function and inhibition.
PDZ-RhoGEF is one member of the Rho guanine exchange factors (RhoGEF) family
important for modulating Rho activity and actin-based cytoskeleton remodeling. PDZ-RhoGEF
possesses a PDZ domain known for complexing with the cytoplasmic tail of Plexin B serving as
modulator for downstream signaling factors. In our study, we found PDZ-RhoGEF complexes with
the Interleukin-8 chemokine receptor, CXCR2. This novel interaction hasn’t been reported before,
and in my dissertation, I solved the crystal structure of PDZ-RhoGEF in complex with the PDZ
motif of CXCR2. Unexpectedly, we identified a disulfide bond linking two PDZ-RhoGEF
molecules. This disulfide bond was previously reported to be important for promoting PDZ-ligand
binding between PDZ-RhoGEF and Plexin B2 peptides. Here, I describe the architecture of the
disulfide-linked PDZ domain of PDZ-RhoGEF in complex with two CXCR2 PDZ-motifs.
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